Runx2	B-DNA
:	O
a	O
novel	O
oncogenic	O
effector	O
revealed	O
by	O
in	O
vivo	O
complementation	O
and	O
retroviral	O
tagging	O
.	O

The	O
Runx2	B-DNA
(	O
Cbfa1	B-DNA
,	O
Pebp2alphaA	B-DNA
,	O
Aml3	B-DNA
)	O
gene	O
was	O
previously	O
identified	O
as	O
a	O
frequent	O
target	O
for	O
transcriptional	O
activation	O
by	O
proviral	O
insertion	O
in	O
T-cell	O
lymphomas	O
of	O
CD2-MYC	O
transgenic	O
mice	O
.	O

We	O
have	O
recently	O
shown	O
that	O
over-expression	O
of	O
the	O
full-length	O
,	O
most	O
highly	O
expressed	O
Runx2	B-DNA
isoform	O
in	O
the	O
thymus	O
perturbs	O
T-cell	O
development	O
,	O
leads	O
to	O
development	O
of	O
spontaneous	O
lymphomas	O
at	O
low	O
frequency	O
and	O
is	O
strongly	O
synergistic	O
with	O
Myc	B-protein
.	O

To	O
gain	O
further	O
insight	O
into	O
the	O
relationship	O
of	O
Runx2	B-DNA
to	O
other	O
lymphomagenic	O
pathways	O
,	O
we	O
tested	O
the	O
effect	O
of	O
combining	O
the	O
CD2-Runx2	B-DNA
transgene	I-DNA
either	O
with	O
a	O
Pim1	B-DNA
transgene	I-DNA
(	O
E	B-DNA
(	I-DNA
mu	I-DNA
)	I-DNA
-Pim1	I-DNA
)	O
or	O
with	O
the	O
p53	B-DNA
null	O
genotype	O
,	O
as	O
each	O
of	O
these	O
displays	O
independent	O
synergy	O
with	O
Myc	B-protein
.	O

In	O
both	O
cases	O
we	O
observed	O
synergistic	O
tumour	O
development	O
.	O

However	O
,	O
Runx2	B-protein
appeared	O
to	O
have	O
a	O
dominant	O
effect	O
on	O
the	O
tumour	O
phenotype	O
in	O
each	O
case	O
,	O
with	O
most	O
tumours	O
conforming	O
to	O
the	O
CD3	O
(	O
+	O
)	O
,	O
CD8	O
(	O
+	O
)	O
,	O
CD4	O
(	O
+/-	O
)	O
phenotype	O
seen	O
in	O
CD2-Runx2	O
mice	O
.	O

Neonatal	O
infection	O
of	O
CD2-Runx2	O
mice	O
with	O
Moloney	O
murine	O
leukaemia	O
virus	O
(	O
Moloney	O
MLV	O
)	O
also	O
led	O
to	O
a	O
dramatic	O
acceleration	O
of	O
tumour	O
onset	O
.	O

Analysis	O
of	O
known	O
Moloney	B-DNA
MLV	I-DNA
target	I-DNA
genes	I-DNA
in	O
these	O
lymphomas	O
showed	O
a	O
high	O
frequency	O
of	O
rearrangement	O
at	O
c-Myc	B-DNA
or	O
N-Myc	B-DNA
(	O
82	O
%	O
)	O
,	O
and	O
a	O
significant	O
number	O
at	O
Pim1	B-DNA
or	O
Pim2	B-DNA
(	O
23	O
%	O
)	O
,	O
and	O
at	O
Pal1/Gfi1	B-DNA
(	O
18	O
%	O
)	O
.	O

These	O
results	O
indicate	O
that	O
Runx2	B-protein
makes	O
a	O
distinct	O
contribution	O
to	O
T-cell	O
lymphoma	O
development	O
which	O
does	O
not	O
coincide	O
with	O
any	O
of	O
the	O
oncogene	O
complementation	O
groups	O
previously	O
identified	O
by	O
retroviral	O
tagging	O
.	O

Oncogene	NULL
(	NULL
2001	NULL
)	NULL
20	NULL
,	NULL
295-302	NULL
©	NULL
2001	NULL
Nature	NULL
Publishing	NULL
Group	NULL
All	NULL
rights	NULL
reserved	NULL
0950-9232/01	NULL
$	NULL
15.00	NULL
a	NULL
www.nature.com/onc	NULL
Runx2	NULL
:	NULL
A	NULL
novel	NULL
oncogenic	NULL
effector	NULL
revealed	NULL
by	NULL
in	NULL
vivo	NULL
complementation	NULL
and	NULL
retroviral	NULL
tagging	NULL
Karen	NULL
Blyth	NULL
'	NULL
,	NULL
Anne	NULL
Terry	NULL
'	NULL
,	NULL
Nancy	NULL
Mackay	NULL
!	NULL

,	NULL
Frangois	NULL
Vaillant	NULL
'	NULL
,	NULL
Margaret	NULL
Bell	NULL
'	NULL
,	NULL
Ewan	NULL
R	NULL
Cameron	NULL
'	NULL
,	NULL
James	NULL
C	NULL
Neil	NULL
!	NULL

and	NULL
Monica	NULL
Stewart*	NULL
'	NULL
'Molecular	NULL
Oncology	NULL
Laboratory	NULL
,	NULL
University	NULL
of	NULL
Glasgow	NULL
Veterinary	NULL
School	NULL
,	NULL
Bearsden	NULL
,	NULL
Glasgow	NULL
,	NULL
G61	NULL
1QH	NULL
,	NULL
UK	NULL
The	NULL
Runx2	NULL
(	NULL
Cbfal	NULL
,	NULL
Pebp2¢A	NULL
,	NULL
gene	NULL
was	NULL
previously	NULL
identified	NULL
as	NULL
a	NULL
frequent	NULL
target	NULL
for	NULL
transcriptional	NULL
activation	NULL
by	NULL
proviral	NULL
insertion	NULL
in	NULL
T-cell	NULL
lymphomas	NULL
of	NULL
CD2-MYC	NULL
transgenic	NULL
mice	NULL
.	NULL

We	NULL
have	NULL
recently	NULL
shown	NULL
that	NULL
over-expression	NULL
of	NULL
the	NULL
full-length	NULL
,	NULL
most	NULL
highly	NULL
expressed	NULL
Runx2	NULL
isoform	NULL
in	NULL
the	NULL
thymus	NULL
perturbs	NULL
T-cell	NULL
development	NULL
,	NULL
leads	NULL
to	NULL
development	NULL
of	NULL
spontaneous	NULL
lymphomas	NULL
at	NULL
low	NULL
frequency	NULL
and	NULL
is	NULL
strongly	NULL
synergistic	NULL
with	NULL
Myc	NULL
.	NULL

To	NULL
gain	NULL
further	NULL
insight	NULL
into	NULL
the	NULL
relationship	NULL
of	NULL
Runx2	NULL
to	NULL
other	NULL
lymphomagenic	NULL
pathways	NULL
,	NULL
we	NULL
tested	NULL
the	NULL
effect	NULL
of	NULL
combining	NULL
the	NULL
CD2-Runx2	NULL
transgene	NULL
either	NULL
with	NULL
a	NULL
Piml	NULL
transgene	NULL
(	NULL
Ep-Pim1l	NULL
)	NULL
or	NULL
with	NULL
the	NULL
p33	NULL
null	NULL
genotype	NULL
,	NULL
as	NULL
each	NULL
of	NULL
these	NULL
displays	NULL
independent	NULL
synergy	NULL
with	NULL
Myc	NULL
.	NULL

In	NULL
both	NULL
cases	NULL
we	NULL
observed	NULL
synergistic	NULL
tumour	NULL
development	NULL
.	NULL

However	NULL
,	NULL
Runx2	NULL
appeared	NULL
to	NULL
have	NULL
a	NULL
dominant	NULL
effect	NULL
on	NULL
the	NULL
tumour	NULL
phenotype	NULL
in	NULL
each	NULL
case	NULL
,	NULL
with	NULL
most	NULL
tumours	NULL
conforming	NULL
to	NULL
the	NULL
CD3*	NULL
,	NULL
CD8	NULL
,	NULL
CD4*'~	NULL
phenotype	NULL
seen	NULL
in	NULL
CD2-Runx2	NULL
mice	NULL
.	NULL

Neonatal	NULL
infection	NULL
of	NULL
CD2-Runx2	NULL
mice	NULL
with	NULL
Moloney	NULL
murine	NULL
leukaemia	NULL
virus	NULL
(	NULL
Moloney	NULL
MLV	NULL
)	NULL
also	NULL
led	NULL
to	NULL
a	NULL
dramatic	NULL
acceleration	NULL
of	NULL
tumour	NULL
onset	NULL
.	NULL

Analysis	NULL
of	NULL
known	NULL
Moloney	NULL
MLV	NULL
target	NULL
genes	NULL
in	NULL
these	NULL
lymphomas	NULL
showed	NULL
a	NULL
high	NULL
frequency	NULL
of	NULL
rearrangement	NULL
at	NULL
c-Myc	NULL
or	NULL
N-Myce	NULL
(	NULL
82	NULL
%	NULL
)	NULL
,	NULL
and	NULL
a	NULL
significant	NULL
number	NULL
at	NULL
Pim	NULL
]	NULL
!	NULL

or	NULL
Pim2	NULL
(	NULL
23	NULL
%	NULL
)	NULL
,	NULL
and	NULL
at	NULL
Pall/Gfil	NULL
(	NULL
18	NULL
%	NULL
)	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
Runx2	NULL
makes	NULL
a	NULL
distinct	NULL
contribution	NULL
to	NULL
T-cell	NULL
lymphoma	NULL
development	NULL
which	NULL
does	NULL
not	NULL
coincide	NULL
with	NULL
any	NULL
of	NULL
the	NULL
oncogene	NULL
complementation	NULL
groups	NULL
previously	NULL
identified	NULL
by	NULL
retroviral	NULL
tagging	NULL
.	NULL

Oncogene	NULL
(	NULL
2001	NULL
)	NULL
20	NULL
,	NULL
295-302	NULL
.	NULL

Keywords	NULL
:	NULL
Runx2	NULL
;	NULL
Chfal	NULL
;	NULL
Myc	NULL
;	NULL
oncogene	NULL
collabora-tion	NULL
;	NULL
retroviral	NULL
tagging	NULL
;	NULL
Runt	NULL
domain	NULL
Introduction	NULL
Manipulation	NULL
of	NULL
the	NULL
mouse	NULL
genome	NULL
can	NULL
be	NULL
used	NULL
to	NULL
model	NULL
the	NULL
somatic	NULL
mutations	NULL
found	NULL
in	NULL
naturally-occurring	NULL
human	NULL
cancers	NULL
with	NULL
the	NULL
aims	NULL
of	NULL
establishing	NULL
their	NULL
etiological	NULL
significance	NULL
and	NULL
determining	NULL
the	NULL
mechanisms	NULL
by	NULL
which	NULL
they	NULL
predispose	NULL
to	NULL
malignancy	NULL
(	NULL
DePinho	NULL
and	NULL
Jacks	NULL
,	NULL
1999	NULL
)	NULL
.	NULL

However	NULL
,	NULL
transgenic	NULL
mice	NULL
*Correspondence	NULL
:	NULL
M	NULL
Stewart	NULL
Received	NULL
14	NULL
July	NULL
2000	NULL
;	NULL
revised	NULL
23	NULL
October	NULL
2000	NULL
;	NULL
accepted	NULL
8	NULL
November	NULL
2000	NULL
also	NULL
serve	NULL
as	NULL
a	NULL
valuable	NULL
resource	NULL
for	NULL
the	NULL
primary	NULL
identification	NULL
of	NULL
the	NULL
genes	NULL
which	NULL
determine	NULL
the	NULL
cancer	NULL
phenotype	NULL
and	NULL
the	NULL
elucidation	NULL
of	NULL
the	NULL
roles	NULL
these	NULL
genes	NULL
play	NULL
in	NULL
normal	NULL
mammalian	NULL
development	NULL
.	NULL

The	NULL
c-Myc	NULL
gene	NULL
has	NULL
been	NULL
the	NULL
subject	NULL
of	NULL
many	NULL
of	NULL
these	NULL
studies	NULL
,	NULL
reflecting	NULL
its	NULL
central	NULL
importance	NULL
in	NULL
tumours	NULL
of	NULL
the	NULL
haemopoietic	NULL
system	NULL
(	NULL
Nesbit	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1999	NULL
)	NULL
.	NULL

The	NULL
known	NULL
mechanisms	NULL
of	NULL
activation	NULL
of	NULL
Myc	NULL
include	NULL
chromosomal	NULL
translocation	NULL
and	NULL
gene	NULL
amplification	NULL
as	NULL
well	NULL
as	NULL
retro-virally	NULL
mediated	NULL
processes	NULL
such	NULL
as	NULL
transduction	NULL
and	NULL
transcriptional	NULL
activation	NULL
by	NULL
viral	NULL
promoter	NULL
or	NULL
enhancer	NULL
insertion	NULL
.	NULL

Studies	NULL
on	NULL
Epu-Myc	NULL
transgenic	NULL
mice	NULL
revealed	NULL
that	NULL
these	NULL
mice	NULL
are	NULL
prone	NULL
to	NULL
develop	NULL
B-cell	NULL
lymphomas	NULL
and	NULL
that	NULL
tumour	NULL
onset	NULL
could	NULL
be	NULL
accelerated	NULL
by	NULL
neonatal	NULL
infection	NULL
with	NULL
Moloney	NULL
MLV	NULL
.	NULL

Analysis	NULL
of	NULL
the	NULL
sites	NULL
of	NULL
insertion	NULL
in	NULL
these	NULL
clonal	NULL
tumours	NULL
revealed	NULL
a	NULL
number	NULL
of	NULL
common	NULL
integration	NULL
sites	NULL
which	NULL
were	NULL
occupied	NULL
in	NULL
independent	NULL
tumours	NULL
and	NULL
the	NULL
elucidation	NULL
of	NULL
a	NULL
series	NULL
of	NULL
genes	NULL
which	NULL
collaborate	NULL
with	NULL
Myc	NULL
in	NULL
lymphomagenesis	NULL
(	NULL
Adams	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1985	NULL
;	NULL
van	NULL
Lohuizen	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
.	NULL

These	NULL
insertion	NULL
sites	NULL
could	NULL
be	NULL
sorted	NULL
into	NULL
complementation	NULL
groups	NULL
on	NULL
the	NULL
basis	NULL
of	NULL
their	NULL
close	NULL
genetic	NULL
linkage	NULL
(	NULL
e.g	NULL
.	NULL

Blal/Bmil	NULL
;	NULL
Gfi1/Eis1/Pal1/Evi5	NULL
)	NULL
or	NULL
the	NULL
functional	NULL
relatedness	NULL
of	NULL
the	NULL
target	NULL
genes	NULL
(	NULL
e.g	NULL
.	NULL

Pim1	NULL
,	NULL
Pim2	NULL
)	NULL
.	NULL

Individual	NULL
tumours	NULL
harbour	NULL
an	NULL
insertion	NULL
at	NULL
only	NULL
a	NULL
single	NULL
locus	NULL
from	NULL
each	NULL
complementation	NULL
group	NULL
,	NULL
indicating	NULL
that	NULL
a	NULL
single	NULL
hit	NULL
to	NULL
each	NULL
pathway	NULL
is	NULL
likely	NULL
to	NULL
be	NULL
sufficient	NULL
for	NULL
lymphoma	NULL
development	NULL
(	NULL
Scheijen	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1997	NULL
)	NULL
.	NULL

Many	NULL
of	NULL
the	NULL
genes	NULL
identified	NULL
as	NULL
Myc-collaborating	NULL
genes	NULL
have	NULL
been	NULL
demonstrated	NULL
to	NULL
be	NULL
oncogenes	NULL
in	NULL
their	NULL
own	NULL
right	NULL
,	NULL
predisposing	NULL
to	NULL
tumour	NULL
development	NULL
when	NULL
expressed	NULL
as	NULL
transgenes	NULL
under	NULL
the	NULL
control	NULL
of	NULL
strong	NULL
tissue-specific	NULL
promoters	NULL
and	NULL
acting	NULL
in	NULL
synergy	NULL
with	NULL
Myc	NULL
when	NULL
the	NULL
transgenes	NULL
are	NULL
combined	NULL
by	NULL
crossing	NULL
of	NULL
mouse	NULL
strains	NULL
(	NULL
Berns	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1999	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
retroviral	NULL
infection	NULL
in	NULL
mice	NULL
transgenic	NULL
for	NULL
Pim	NULL
]	NULL
or	NULL
Bmil	NULL
leads	NULL
to	NULL
acceleration	NULL
of	NULL
tumour	NULL
onset	NULL
with	NULL
insertional	NULL
activation	NULL
of	NULL
c-Myc	NULL
or	NULL
N-Myce	NULL
as	NULL
frequent	NULL
events	NULL
(	NULL
van	NULL
Lohuizen	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
;	NULL
Alkema	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1997	NULL
)	NULL
.	NULL

These	NULL
observations	NULL
support	NULL
a	NULL
model	NULL
of	NULL
lymphomagenesis	NULL
involving	NULL
at	NULL
least	NULL
three	NULL
oncogenic	NULL
complementation	NULL
groups	NULL
in	NULL
which	NULL
the	NULL
relevant	NULL
target	NULL
genes	NULL
are	NULL
of	NULL
the	NULL
Myc	NULL
family	NULL
(	NULL
c-Myc	NULL
or	NULL
N-Myc	NULL
)	NULL
,	NULL
the	NULL
Pim	NULL
family	NULL
(	NULL
Pim1	NULL
,	NULL
Pim2	NULL
,	NULL
Pim3	NULL
)	NULL
and	NULL
a	NULL
less	NULL
well-defined	NULL
third	NULL
group	NULL
in	NULL
which	NULL
the	NULL
critical	NULL
targets	NULL
appear	NULL
to	NULL
be	NULL
Bmil	NULL
and	NULL
Gfil	NULL
.	NULL

Surprisingly	NULL
,	NULL
our	NULL
studies	NULL
on	NULL
mice	NULL
carrying	NULL
a	NULL
MYC	NULL
transgene	NULL
expressed	NULL
in	NULL
the	NULL
T-cell	NULL
lineage	NULL
under	NULL
the	NULL
Runx2	NULL
,	NULL
in	NULL
vivo	NULL
complementation	NULL
and	NULL
retroviral	NULL
tagging	NULL
K	NULL
Blyth	NULL
et	NULL
al	NULL
296	NULL
control	NULL
of	NULL
a	NULL
CD2	NULL
locus	NULL
control	NULL
region	NULL
(	NULL
CD2-MYC	NULL
)	NULL
showed	NULL
that	NULL
tumour	NULL
onset	NULL
could	NULL
be	NULL
accelerated	NULL
by	NULL
Moloney	NULL
MLV	NULL
but	NULL
with	NULL
only	NULL
a	NULL
low	NULL
frequency	NULL
of	NULL
hits	NULL
at	NULL
the	NULL
known	NULL
Myc	NULL
collaborating	NULL
genes	NULL
(	NULL
Stewart	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
.	NULL

Instead	NULL
,	NULL
we	NULL
defined	NULL
the	NULL
Ti/	NULL
!	NULL

locus	NULL
as	NULL
a	NULL
common	NULL
target	NULL
in	NULL
a	NULL
significant	NULL
proportion	NULL
of	NULL
tumours	NULL
and	NULL
we	NULL
have	NULL
subsequently	NULL
shown	NULL
that	NULL
these	NULL
insertions	NULL
activate	NULL
transcription	NULL
of	NULL
the	NULL
Runx2/Cbfal/Aml3/Pebp2	NULL
«	NULL
A	NULL
gene	NULL
(	NULL
hereafter	NULL
Runx	NULL
?	NULL
)	NULL

(	NULL
Stewart	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
,	NULL
1997	NULL
)	NULL
.	NULL

By	NULL
a	NULL
similar	NULL
approach	NULL
,	NULL
Girard	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
showed	NULL
that	NULL
Notch1	NULL
is	NULL
the	NULL
preferred	NULL
target	NULL
for	NULL
viral	NULL
acceleration/	NULL
activation	NULL
in	NULL
their	NULL
MMTVd-Myec	NULL
transgenic	NULL
model	NULL
.	NULL

Together	NULL
,	NULL
these	NULL
results	NULL
suggest	NULL
that	NULL
the	NULL
preferred	NULL
collaborating	NULL
genes	NULL
for	NULL
Myc	NULL
vary	NULL
according	NULL
to	NULL
target	NULL
cell	NULL
and	NULL
host	NULL
genetic	NULL
background	NULL
.	NULL

Moreover	NULL
,	NULL
a	NULL
recent	NULL
high	NULL
throughput	NULL
screen	NULL
of	NULL
retroviral	NULL
insertion	NULL
sites	NULL
in	NULL
myeloid	NULL
leukaemias	NULL
of	NULL
BXH2	NULL
and	NULL
AKXD	NULL
recombinant	NULL
inbred	NULL
mice	NULL
which	NULL
identified	NULL
many	NULL
new	NULL
common	NULL
insertion	NULL
sites	NULL
in	NULL
addition	NULL
to	NULL
known	NULL
targets	NULL
,	NULL
indicates	NULL
that	NULL
this	NULL
screening	NULL
approach	NULL
is	NULL
far	NULL
from	NULL
exhausted	NULL
(	NULL
Li	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1999	NULL
)	NULL
.	NULL

Runx2	NULL
?	NULL

is	NULL
one	NULL
member	NULL
of	NULL
the	NULL
Core	NULL
Binding	NULL
Factor	NULL
(	NULL
CBF	NULL
)	NULL
family	NULL
,	NULL
a	NULL
set	NULL
of	NULL
heterodimeric	NULL
regulatory	NULL
proteins	NULL
with	NULL
vital	NULL
roles	NULL
in	NULL
haemopoiesis	NULL
and	NULL
osteogen-esis	NULL
.	NULL

Family	NULL
members	NULL
encode	NULL
a	NULL
protein	NULL
with	NULL
a	NULL
conserved	NULL
region	NULL
of	NULL
128	NULL
amino	NULL
acids	NULL
called	NULL
the	NULL
Runt	NULL
Domain	NULL
,	NULL
which	NULL
is	NULL
highly	NULL
homologous	NULL
to	NULL
a	NULL
region	NULL
of	NULL
the	NULL
Drosophila	NULL
Runt	NULL
protein	NULL
(	NULL
Kania	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
.	NULL

Whereas	NULL
the	NULL
other	NULL
two	NULL
members	NULL
of	NULL
the	NULL
mammalian	NULL
CBF	NULL
alpha	NULL
family	NULL
,	NULL
Runx1/Cbfa2/Ami1/Pebp	NULL
?	NULL

«	NULL
B	NULL
and	NULL
Runx3/Cbfa3/	NULL
Aml2/Pebp2	NULL
«	NULL
4C	NULL
,	NULL
(	NULL
hereafter	NULL
Runx1	NULL
,	NULL
Runx3	NULL
)	NULL
are	NULL
expressed	NULL
in	NULL
a	NULL
wide	NULL
range	NULL
of	NULL
haemopoietic	NULL
cells	NULL
,	NULL
the	NULL
expression	NULL
of	NULL
Runx2	NULL
?	NULL

is	NULL
more	NULL
restricted	NULL
and	NULL
had	NULL
been	NULL
described	NULL
only	NULL
in	NULL
T-cells	NULL
and	NULL
in	NULL
non-lymphoid	NULL
cells	NULL
such	NULL
as	NULL
3T3	NULL
and	NULL
Buffalo	NULL
rat	NULL
liver	NULL
cells	NULL
(	NULL
Ogawa	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
;	NULL
Satake	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
;	NULL
Meyers	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
.	NULL

More	NULL
recently	NULL
however	NULL
,	NULL
we	NULL
and	NULL
others	NULL
have	NULL
shown	NULL
high	NULL
levels	NULL
of	NULL
Runx2	NULL
expression	NULL
in	NULL
cells	NULL
of	NULL
the	NULL
bone	NULL
forming	NULL
lineages	NULL
(	NULL
Stewart	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1997	NULL
;	NULL
Ducy	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1997	NULL
)	NULL
,	NULL
an	NULL
observation	NULL
confirmed	NULL
by	NULL
gene	NULL
inactivation	NULL
studies	NULL
which	NULL
demonstrated	NULL
the	NULL
crucial	NULL
role	NULL
played	NULL
by	NULL
Runx2	NULL
in	NULL
bone	NULL
development	NULL
(	NULL
Komori	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1997	NULL
;	NULL
Otto	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1997	NULL
)	NULL
.	NULL

Runxl	NULL
is	NULL
essential	NULL
for	NULL
the	NULL
initiation	NULL
of	NULL
definitive	NULL
haemopoiesis	NULL
(	NULL
Okuda	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
;	NULL
Wang	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
;	NULL
North	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1999	NULL
)	NULL
.	NULL

Significantly	NULL
,	NULL
RUNXI/CBFA	NULL
?	NULL

and	NULL
CBFB	NULL
,	NULL
the	NULL
gene	NULL
encoding	NULL
the	NULL
beta	NULL
subunit	NULL
,	NULL
are	NULL
frequently	NULL
disrupted	NULL
in	NULL
several	NULL
types	NULL
of	NULL
human	NULL
leukaemia	NULL
(	NULL
Look	NULL
,	NULL
1997	NULL
)	NULL
.	NULL

We	NULL
have	NULL
shown	NULL
recently	NULL
that	NULL
over-expression	NULL
of	NULL
the	NULL
major	NULL
full-length	NULL
Runx2	NULL
isoform	NULL
in	NULL
the	NULL
thymus	NULL
perturbs	NULL
T-cell	NULL
development	NULL
,	NULL
leads	NULL
to	NULL
the	NULL
development	NULL
of	NULL
spontaneous	NULL
lymphomas	NULL
at	NULL
low	NULL
frequency	NULL
and	NULL
is	NULL
strongly	NULL
synergistic	NULL
with	NULL
Myc	NULL
(	NULL
Vaillant	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1999	NULL
)	NULL
.	NULL

In	NULL
this	NULL
study	NULL
we	NULL
have	NULL
investigated	NULL
the	NULL
relationship	NULL
of	NULL
Runx2	NULL
to	NULL
other	NULL
lymphomagenic	NULL
pathways	NULL
.	NULL

We	NULL
show	NULL
that	NULL
in	NULL
addition	NULL
to	NULL
the	NULL
strong	NULL
synergy	NULL
exhibited	NULL
between	NULL
Runx2	NULL
and	NULL
Myc	NULL
,	NULL
Runx2	NULL
can	NULL
collaborate	NULL
independently	NULL
with	NULL
the	NULL
p53	NULL
null	NULL
genotype	NULL
and	NULL
with	NULL
a	NULL
Pim1	NULL
oncogene	NULL
.	NULL

Retroviral	NULL
infection	NULL
of	NULL
Runx2	NULL
transgenic	NULL
mice	NULL
accelerates	NULL
tumour	NULL
development	NULL
with	NULL
preferential	NULL
targeting	NULL
of	NULL
Myc	NULL
family	NULL
genes	NULL
,	NULL
though	NULL
Oncogene	NULL
insertions	NULL
were	NULL
also	NULL
found	NULL
at	NULL
Pim	NULL
]	NULL
or	NULL
Pim2	NULL
and	NULL
at	NULL
the	NULL
Pall/Gfil	NULL
locus	NULL
.	NULL

Our	NULL
results	NULL
demonstrate	NULL
that	NULL
Runx2	NULL
contributes	NULL
to	NULL
T-cell	NULL
lymphoma	NULL
development	NULL
in	NULL
a	NULL
unique	NULL
manner	NULL
with	NULL
a	NULL
dominant	NULL
effect	NULL
on	NULL
the	NULL
tumour	NULL
cell	NULL
lineage	NULL
and	NULL
phenotype	NULL
.	NULL

Results	NULL
Moloney	NULL
MLV	NULL
accelerates	NULL
the	NULL
development	NULL
of	NULL
T-cell	NULL
lymphomas	NULL
in	NULL
CD2-Runx2	NULL
mice	NULL
CD2-Runx2-G1	NULL
(	NULL
hereafter	NULL
CD2-Runx2	NULL
)	NULL
transgenic	NULL
mice	NULL
develop	NULL
T-cell	NULL
lymphoma	NULL
with	NULL
low	NULL
frequency	NULL
and	NULL
display	NULL
strongly	NULL
synergistic	NULL
tumour	NULL
development	NULL
in	NULL
crosses	NULL
with	NULL
MYC	NULL
transgenic	NULL
mice	NULL
(	NULL
Vaillant	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1999	NULL
)	NULL
.	NULL

In	NULL
view	NULL
of	NULL
the	NULL
low	NULL
spontaneous	NULL
tumour	NULL
rate	NULL
in	NULL
CD2-Runx2	NULL
mice	NULL
we	NULL
were	NULL
interested	NULL
to	NULL
discover	NULL
whether	NULL
virus	NULL
infection	NULL
would	NULL
accelerate	NULL
tumour	NULL
formation	NULL
.	NULL

Newborn	NULL
CD2-Runx2	NULL
mice	NULL
and	NULL
nontransgenic	NULL
littermates	NULL
were	NULL
infected	NULL
with	NULL
Moloney	NULL
MLV	NULL
(	NULL
Figure	NULL
1	NULL
)	NULL
.	NULL

The	NULL
presence	NULL
of	NULL
the	NULL
transgene	NULL
significantly	NULL
reduced	NULL
the	NULL
latent	NULL
period	NULL
for	NULL
lymphoma	NULL
development	NULL
in	NULL
Moloney	NULL
MLV-infected	NULL
animals	NULL
(	NULL
P	NULL
<	NULL
0.001	NULL
when	NULL
compared	NULL
to	NULL
infected	NULL
littermate	NULL
controls	NULL
)	NULL
.	NULL

By	NULL
97	NULL
days	NULL
,	NULL
100	NULL
%	NULL
of	NULL
CD2-Runx2	NULL
infected	NULL
animals	NULL
(	NULL
#	NULL
=46	NULL
)	NULL
had	NULL
developed	NULL
thymic	NULL
lymphoma	NULL
in	NULL
contrast	NULL
to	NULL
only	NULL
30	NULL
%	NULL
(	NULL
6/20	NULL
)	NULL
of	NULL
infected	NULL
littermate	NULL
controls	NULL
and	NULL
O0/117	NULL
uninfected	NULL
CD2-Runx2	NULL
mice	NULL
.	NULL

Infected	NULL
CD2-Runx2	NULL
transgenic	NULL
mice	NULL
presented	NULL
with	NULL
grossly	NULL
enlarged	NULL
thymus	NULL
and	NULL
frequent	NULL
involvement	NULL
of	NULL
secondary	NULL
lymphoid	NULL
organs	NULL
,	NULL
particularly	NULL
splenic	NULL
en-largement	NULL
.	NULL

Tumour	NULL
cells	NULL
were	NULL
clonal	NULL
and	NULL
of	NULL
T-cell	NULL
origin	NULL
as	NULL
determined	NULL
by	NULL
proviral	NULL
integration	NULL
patterns	NULL
and	NULL
rearrangement	NULL
of	NULL
the	NULL
TCR-CB	NULL
and	NULL
JB	NULL
chain	NULL
genes	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Flow	NULL
cytometry	NULL
analysis	NULL
for	NULL
the	NULL
cell	NULL
-e-	NULL
CD2-Runx2	NULL
)	NULL
MLV	NULL
«	NULL
O+	NULL
control/MLV	NULL
-r-	NULL
CD2-Runx2	NULL
%	NULL
Lymphoma	NULL
Free	NULL
Survival	NULL
120	NULL
30	NULL
60	NULL
90	NULL
Time	NULL
{	NULL
days	NULL
)	NULL
Figure	NULL
1	NULL
Acceleration	NULL
of	NULL
tumour	NULL
onset	NULL
in	NULL
Moloney-MLV	NULL
infected	NULL
CD2-Runx2	NULL
transgenic	NULL
mice	NULL
.	NULL

The	NULL
Y-axis	NULL
shows	NULL
the	NULL
percentage	NULL
of	NULL
lymphoma-free	NULL
survivors	NULL
with	NULL
time	NULL
in	NULL
days	NULL
(	NULL
X-axis	NULL
)	NULL
.	NULL

Survival	NULL
curves	NULL
are	NULL
shown	NULL
for	NULL
CD2-Runx2	NULL
mice	NULL
infected	NULL
with	NULL
Moloney-MLV	NULL
(	NULL
filled	NULL
circles	NULL
,	NULL
1	NULL
»	NULL
=46	NULL
)	NULL
,	NULL
control	NULL
littermate	NULL
mice	NULL
infected	NULL
with	NULL
Moloney-MLV	NULL
(	NULL
empty	NULL
circles	NULL
,	NULL
»	NULL
=20	NULL
)	NULL
and	NULL
uninfected	NULL
CD2-Runx2	NULL
mice	NULL
(	NULL
filled	NULL
triangles	NULL
,	NULL
n=117	NULL
)	NULL
surface	NULL
antigen	NULL
combinations	NULL
CD3/CD45SR	NULL
and	NULL
CD4/	NULL
CD8	NULL
was	NULL
performed	NULL
on	NULL
cells	NULL
prepared	NULL
from	NULL
virus-accelerated	NULL
tumours	NULL
.	NULL

The	NULL
cells	NULL
of	NULL
all	NULL
tumours	NULL
analysed	NULL
were	NULL
CD3	NULL
+/CD45R-	NULL
confirming	NULL
their	NULL
T-cell	NULL
origin	NULL
.	NULL

19/	NULL
21	NULL
tumours	NULL
analysed	NULL
presented	NULL
as	NULL
a	NULL
clonal	NULL
population	NULL
of	NULL
CD4/CD8	NULL
double	NULL
positive	NULL
(	NULL
DP	NULL
)	NULL
cells	NULL
or	NULL
as	NULL
a	NULL
clonal	NULL
population	NULL
of	NULL
CD4CD8DP	NULL
and	NULL
CD8	NULL
single	NULL
positive	NULL
(	NULL
SP	NULL
)	NULL
cells	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

The	NULL
finding	NULL
that	NULL
Moloney-MLV	NULL
accelerated	NULL
Runx2-expressing	NULL
tumours	NULL
invariably	NULL
express	NULL
CD8	NULL
reflects	NULL
the	NULL
surface	NULL
phenotype	NULL
in	NULL
preneo-plastic	NULL
thymus	NULL
from	NULL
CD2-Runx2	NULL
mice	NULL
which	NULL
consistently	NULL
show	NULL
an	NULL
expanded	NULL
CD8*	NULL
population	NULL
(	NULL
Vaillant	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1999	NULL
)	NULL
,	NULL
and	NULL
contrasts	NULL
with	NULL
the	NULL
more	NULL
variable	NULL
phenotype	NULL
observed	NULL
in	NULL
infected	NULL
littermate	NULL
controls	NULL
(	NULL
Lazo	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
;	NULL
Clark	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
.	NULL

Myc	NULL
loci	NULL
are	NULL
the	NULL
preferred	NULL
integration	NULL
targets	NULL
in	NULL
accelerated	NULL
CD2-Runx2	NULL
tumours	NULL
DNA	NULL
was	NULL
prepared	NULL
from	NULL
CD2-Runx2	NULL
accelerated	NULL
tumours	NULL
and	NULL
Southern	NULL
blot	NULL
analysis	NULL
performed	NULL
to	NULL
determined	NULL
where	NULL
Moloney	NULL
MLV	NULL
had	NULL
integrated	NULL
.	NULL

Rearrangement	NULL
of	NULL
the	NULL
following	NULL
genes/loci	NULL
was	NULL
assessed	NULL
Table	NULL
1	NULL
Thymocytes	NULL
from	NULL
Moloney	NULL
MLV-infected	NULL
CD2-Runx2	NULL
,	NULL
CD2-Runx2/p53~~-	NULL
,	NULL
CD2-Runx2/Eu-Pim1l	NULL
and	NULL
CD2-Runx2/MYC	NULL
)	NULL
Eu-Pim1	NULL
mice	NULL
display	NULL
a	NULL
consistent	NULL
T-cell	NULL
phenotype	NULL
Genotype	NULL
DN	NULL
CD4*	NULL
CD8*	NULL
CD4*/CD8*	NULL
DP	NULL
``	NULL
/CD8*	NULL
CD2Runx2/MLV	NULL
100	NULL
1	NULL
0	NULL
13	NULL
6	NULL
n=21	NULL
CD2	NULL
0	NULL
0	NULL
1	NULL
1	NULL
2	NULL
n=4	NULL
-/-	NULL
0	NULL
_	NULL
0	NULL
1	NULL
0	NULL
14	NULL
n=15	NULL
CD2	NULL
0	NULL
0	NULL
0	NULL
0	NULL
4	NULL
n=4	NULL
'CD4~/CD8~	NULL
;	NULL
°CD4*/CD8	NULL
*	NULL
c-Myc	NULL
:	NULL
$	NULL
2	NULL
%	NULL
Runx2	NULL
,	NULL
in	NULL
vivo	NULL
complementation	NULL
and	NULL
retroviral	NULL
tagging	NULL
K	NULL
Blyth	NULL
et	NULL
al	NULL
using	NULL
the	NULL
indicated	NULL
restriction	NULL
enzymes	NULL
:	NULL
c-Myc	NULL
,	NULL
N-Myc	NULL
,	NULL
Gfil	NULL
,	NULL
Pall	NULL
,	NULL
Ticl	NULL
,	NULL
Pim2	NULL
,	NULL
Dsil	NULL
(	NULL
Kpnl	NULL
)	NULL
,	NULL
Pim1	NULL
,	NULL
Bmil	NULL
,	NULL
Ahil	NULL
,	NULL
Evi5	NULL
,	NULL
(	NULL
EcoRI	NULL
)	NULL
,	NULL
Runx1	NULL
and	NULL
p53	NULL
(	NULL
EcoRV	NULL
)	NULL
.	NULL

25/44	NULL
of	NULL
the	NULL
CD2-Runx2	NULL
tumours	NULL
had	NULL
integrations	NULL
in	NULL
the	NULL
c-Myc	NULL
locus	NULL
,	NULL
six	NULL
had	NULL
integrations	NULL
in	NULL
the	NULL
N-Myc	NULL
locus	NULL
and	NULL
five	NULL
tumours	NULL
had	NULL
both	NULL
c-	NULL
and	NULL
N-Myc	NULL
integrations	NULL
.	NULL

Therefore	NULL
,	NULL
in	NULL
82	NULL
%	NULL
of	NULL
tumours	NULL
,	NULL
the	NULL
Moloney	NULL
MLV	NULL
provirus	NULL
had	NULL
inserted	NULL
into	NULL
either	NULL
the	NULL
c-	NULL
or	NULL
N-Mye	NULL
loci	NULL
(	NULL
Figure	NULL
2	NULL
)	NULL
.	NULL

This	NULL
is	NULL
a	NULL
significant	NULL
increase	NULL
when	NULL
compared	NULL
to	NULL
non-transgenic	NULL
littermates	NULL
,	NULL
(	NULL
7/18	NULL
,	NULL
P	NULL
<	NULL
0.002	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
a	NULL
number	NULL
of	NULL
integrations	NULL
were	NULL
observed	NULL
in	NULL
the	NULL
Pim1/Pim2	NULL
(	NULL
10/44	NULL
)	NULL
and	NULL
Gfil/Pall	NULL
(	NULL
8/44	NULL
)	NULL
complementation	NULL
groups	NULL
defined	NULL
by	NULL
retroviral	NULL
tagging	NULL
in	NULL
B-cell	NULL
lymphomas	NULL
of	NULL
Eu-Myc	NULL
mice	NULL
(	NULL
Berns	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1999	NULL
)	NULL
.	NULL

It	NULL
is	NULL
clear	NULL
that	NULL
more	NULL
than	NULL
one	NULL
insertion	NULL
can	NULL
be	NULL
detected	NULL
in	NULL
a	NULL
significant	NULL
number	NULL
of	NULL
tumours	NULL
in	NULL
both	NULL
transgenic	NULL
and	NULL
non-transgenic	NULL
cohorts	NULL
(	NULL
Figure	NULL
2	NULL
)	NULL
.	NULL

These	NULL
results	NULL
emphasize	NULL
the	NULL
strong	NULL
collaboration	NULL
displayed	NULL
by	NULL
Runx2	NULL
?	NULL

2	NULL
and	NULL
Myc	NULL
in	NULL
T-cell	NULL
lymphomagen-esis	NULL
.	NULL

Furthermore	NULL
,	NULL
the	NULL
ability	NULL
of	NULL
Runx2	NULL
to	NULL
collaborate	NULL
with	NULL
genes	NULL
from	NULL
each	NULL
of	NULL
the	NULL
established	NULL
gene	NULL
complementation	NULL
groups	NULL
of	NULL
transformation	NULL
indicates	NULL
that	NULL
Runx2	NULL
makes	NULL
a	NULL
distinct	NULL
contribution	NULL
to	NULL
T-cell	NULL
lymphoma	NULL
in	NULL
this	NULL
system	NULL
and	NULL
suggests	NULL
that	NULL
Runx2	NULL
belongs	NULL
to	NULL
a	NULL
novel	NULL
gene	NULL
complementation	NULL
group	NULL
.	NULL

CD2-Runx2	NULL
transgenic	NULL
mice	NULL
display	NULL
strongly	NULL
synergistic	NULL
tumour	NULL
development	NULL
with	NULL
transgenic	NULL
mice	NULL
and	NULL
mice	NULL
deficient	NULL
for	NULL
p53	NULL
The	NULL
high	NULL
frequency	NULL
of	NULL
viral	NULL
integration	NULL
in	NULL
the	NULL
Myc	NULL
loci	NULL
observed	NULL
in	NULL
CD2-Runx2	NULL
virus	NULL
accelerated	NULL
tumours	NULL
and	NULL
the	NULL
strong	NULL
synergy	NULL
displayed	NULL
by	NULL
both	NULL
CD2-Runx2/	NULL
CD2-MYC	NULL
transgenic	NULL
mice	NULL
(	NULL
Vaillant	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1999	NULL
)	NULL
and	NULL
CD2-MYC/p53	NULL
null	NULL
mice	NULL
(	NULL
Blyth	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
prompted	NULL
us	NULL
to	NULL
explore	NULL
the	NULL
effects	NULL
of	NULL
Runx2	NULL
on	NULL
a	NULL
p53	NULL
deficient	NULL
background	NULL
.	NULL

This	NULL
was	NULL
examined	NULL
by	NULL
cross-mating	NULL
p53	NULL
homozygous	NULL
null	NULL
mice	NULL
(	NULL
p53~~-	NULL
)	NULL
with	NULL
CD2-Runx2	NULL
N-Mye	NULL
Pim1,2:23	NULL
%	NULL
Pim1,2:22	NULL
%	NULL
Tg*	NULL
,	NULL
n=44	NULL
Pall	NULL
..	NULL
,	NULL
ofi	NULL
**	NULL
control	NULL
,	NULL
n=18	NULL
Figure	NULL
2	NULL
Venn	NULL
diagrams	NULL
depicting	NULL
proviral	NULL
integrations	NULL
in	NULL
the	NULL
Moloney-MLV	NULL
induced	NULL
tumours	NULL
in	NULL
CD2-Runx2	NULL
transgenic	NULL
mice	NULL
.	NULL

Circle	NULL
size	NULL
is	NULL
proportional	NULL
to	NULL
the	NULL
number	NULL
of	NULL
proviral	NULL
integrations	NULL
observed	NULL
,	NULL
overlaps	NULL
are	NULL
not	NULL
proportional	NULL
.	NULL

Tg*	NULL
;	NULL
CD2-Runx2	NULL
transgenic	NULL
animals	NULL
(	NULL
#	NULL
=44	NULL
)	NULL
,	NULL
Control	NULL
;	NULL
nontransgenic	NULL
littermate	NULL
controls	NULL
(	NULL
2=18	NULL
)	NULL
.	NULL

36	NULL
of	NULL
44	NULL
T-cell	NULL
lymphomas	NULL
in	NULL
the	NULL
Runx2	NULL
transgenic	NULL
cohort	NULL
harbour	NULL
integrations	NULL
in	NULL
the	NULL
c-Myc	NULL
or	NULL
N-Myc	NULL
loci	NULL
as	NULL
compared	NULL
to	NULL
7	NULL
of	NULL
18	NULL
in	NULL
the	NULL
non-transgenic	NULL
littermate	NULL
controls	NULL
.	NULL

Integrations	NULL
were	NULL
also	NULL
observed	NULL
in	NULL
the	NULL
Pim1	NULL
,	NULL
2	NULL
loci	NULL
(	NULL
Runx2	NULL
transgenic	NULL
,	NULL
10/44	NULL
:	NULL
littermate	NULL
controls	NULL
,	NULL
4/18	NULL
)	NULL
and	NULL
Gfl/Pall	NULL
loci	NULL
(	NULL
Runx2	NULL
transgenic	NULL
,	NULL
8/44	NULL
:	NULL
littermate	NULL
controls	NULL
,	NULL
6/18	NULL
)	NULL
297	NULL
Oncogene	NULL
Runx2	NULL
,	NULL
in	NULL
vivo	NULL
complementation	NULL
and	NULL
retroviral	NULL
tagging	NULL
K	NULL
Blyth	NULL
et	NULL
al	NULL
298	NULL
transgenic	NULL
mice	NULL
and	NULL
then	NULL
back	NULL
crossing	NULL
with	NULL
p53~_-mice	NULL
to	NULL
generate	NULL
a	NULL
cohort	NULL
of	NULL
CD2-Runx2	NULL
transgenic	NULL
mice	NULL
on	NULL
null	NULL
and	NULL
heterozygous	NULL
(	NULL
p53~*	NULL
)	NULL
back-grounds	NULL
.	NULL

This	NULL
breeding	NULL
also	NULL
generated	NULL
additional	NULL
littermate	NULL
controls	NULL
of	NULL
p53w_~-	NULL
and	NULL
p53~*	NULL
without	NULL
a	NULL
CD2-Runx2	NULL
transgene	NULL
.	NULL

CD2-Runx2	NULL
mice	NULL
develop	NULL
spontaneous	NULL
T-cell	NULL
tumours	NULL
at	NULL
low	NULL
frequency	NULL
with	NULL
extensive	NULL
involvement	NULL
of	NULL
lymphoid	NULL
tissues	NULL
(	NULL
Vaillant	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1999	NULL
)	NULL
while	NULL
mice	NULL
deficient	NULL
in	NULL
p53	NULL
all	NULL
succumb	NULL
to	NULL
a	NULL
variety	NULL
of	NULL
tumours	NULL
,	NULL
including	NULL
T-cell	NULL
lymphoma	NULL
,	NULL
by	NULL
10	NULL
months	NULL
(	NULL
Donehower	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
;	NULL
Harvey	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
.	NULL

A	NULL
dramatic	NULL
acceleration	NULL
in	NULL
the	NULL
rate	NULL
of	NULL
tumour	NULL
onset	NULL
was	NULL
observed	NULL
in	NULL
animals	NULL
which	NULL
were	NULL
CD2-Runx2	NULL
transgene	NULL
positive	NULL
and	NULL
homozygous	NULL
null	NULL
for	NULL
p53	NULL
(	NULL
Figure	NULL
3a	NULL
)	NULL
.	NULL

A	NULL
cohort	NULL
of	NULL
-	NULL
@	NULL
-	NULL
Runx2	NULL
)	NULL
pSSnull	NULL
-O-	NULL
Runx2	NULL
/	NULL
pSShetero	NULL
-¥-	NULL
-v-	NULL
pSShetero	NULL
%	NULL
tumour	NULL
free	NULL
survival	NULL
\	NULL
t	NULL
%	NULL
i	NULL
x	NULL
X	NULL
\	NULL
0	NULL
r	NULL
r	NULL
-	NULL
#	NULL
-	NULL
v	NULL
0	NULL
30	NULL
_	NULL
60	NULL
90	NULL
t	NULL
t	NULL
7	NULL
t	NULL
r	NULL
-	NULL
t	NULL
120	NULL
150	NULL
180	NULL
210	NULL
240	NULL
270	NULL
300	NULL
330	NULL
Time	NULL
(	NULL
days	NULL
)	NULL
80	NULL
70	NULL
-	NULL
#	NULL
-	NULL
Runx2	NULL
/	NULL
Pim1	NULL
=O	NULL
Runx2	NULL
-y-	NULL
Pim1	NULL
-y	NULL
non	NULL
transgenic	NULL
60	NULL
50	NULL
40	NULL
4	NULL
%	NULL
tumour	NULL
free	NULL
survival	NULL
30	NULL
4	NULL
20	NULL
-	NULL
t	NULL
t	NULL
r	NULL
r	NULL
t	NULL
t	NULL
t	NULL
u	NULL
1	NULL
0	NULL
30	NULL
60	NULL
90	NULL
120	NULL
150	NULL
180	NULL
_	NULL
210	NULL
-	NULL
240	NULL
-	NULL
270	NULL
200	NULL
Time	NULL
(	NULL
days	NULL
)	NULL
Figure	NULL
3	NULL
Acceleration	NULL
of	NULL
tumour	NULL
onset	NULL
in	NULL
CD2-Runx2	NULL
mice	NULL
crossed	NULL
with	NULL
p53	NULL
null	NULL
and	NULL
Eu-Pim1	NULL
mice	NULL
.	NULL

(	NULL
a	NULL
)	NULL
Tumour	NULL
free	NULL
survival	NULL
of	NULL
CD2-Runx2	NULL
transgenic	NULL
mice	NULL
crossed	NULL
with	NULL
p33	NULL
null	NULL
mice	NULL
.	NULL

Percentage	NULL
survival	NULL
against	NULL
time	NULL
is	NULL
shown	NULL
for	NULL
CD2-Runx2/p353	NULL
null	NULL
(	NULL
filled	NULL
circles	NULL
,	NULL
n=24	NULL
)	NULL
,	NULL
CD2-Runx2/p53	NULL
heterozygote	NULL
(	NULL
open	NULL
circles	NULL
,	NULL
n=36	NULL
)	NULL
,	NULL
p53	NULL
null	NULL
(	NULL
filled	NULL
triangles	NULL
,	NULL
n=20	NULL
)	NULL
and	NULL
p33	NULL
heterozygote	NULL
(	NULL
open	NULL
triangles	NULL
,	NULL
»	NULL
n=48	NULL
)	NULL
animals	NULL
.	NULL

(	NULL
b	NULL
)	NULL
Tumour	NULL
free	NULL
survival	NULL
of	NULL
CD2-Runx2/Eu-Pim1	NULL
animals	NULL
(	NULL
filled	NULL
circles	NULL
,	NULL
n=25	NULL
)	NULL
is	NULL
shown	NULL
with	NULL
littermate	NULL
controls	NULL
CD2-Runx2	NULL
(	NULL
open	NULL
circles	NULL
,	NULL
»	NULL
=40	NULL
)	NULL
,	NULL
Eu-Pim1	NULL
(	NULL
filled	NULL
triangles	NULL
,	NULL
n=12	NULL
)	NULL
and	NULL
non	NULL
transgenic	NULL
animals	NULL
(	NULL
open	NULL
triangles	NULL
,	NULL
n=	NULL
12	NULL
)	NULL
Oncogene	NULL
24	NULL
CD2-Runx2/p53-_~-	NULL
animals	NULL
developed	NULL
spontaneous	NULL
T-cell	NULL
lymphomas	NULL
with	NULL
100	NULL
%	NULL
incidence	NULL
between	NULL
64	NULL
and	NULL
102	NULL
days	NULL
.	NULL

The	NULL
reduced	NULL
latency	NULL
in	NULL
the	NULL
tumour	NULL
development	NULL
of	NULL
these	NULL
mice	NULL
was	NULL
highly	NULL
significant	NULL
(	NULL
P	NULL
<	NULL
0.001	NULL
)	NULL
when	NULL
compared	NULL
to	NULL
the	NULL
control	NULL
groups	NULL
in	NULL
the	NULL
study	NULL
.	NULL

The	NULL
pathological	NULL
profile	NULL
in	NULL
the	NULL
CD2-Runx2/	NULL
p53-_~-	NULL
mice	NULL
differed	NULL
from	NULL
the	NULL
CD2-Runx2	NULL
mice	NULL
in	NULL
that	NULL
tumours	NULL
were	NULL
restricted	NULL
almost	NULL
entirely	NULL
to	NULL
the	NULL
thymus	NULL
with	NULL
little	NULL
or	NULL
no	NULL
involvement	NULL
of	NULL
secondary	NULL
lymphoid	NULL
organs	NULL
.	NULL

To	NULL
assess	NULL
possible	NULL
functional	NULL
redundancy	NULL
between	NULL
the	NULL
Runx2	NULL
oncogene	NULL
and	NULL
known	NULL
Myc-collaborating	NULL
genes	NULL
in	NULL
T-cell	NULL
lymphomagenesis	NULL
,	NULL
the	NULL
CD2-Runx2	NULL
mice	NULL
were	NULL
crossed	NULL
with	NULL
mice	NULL
carrying	NULL
the	NULL
Pim	NULL
]	NULL
transgene	NULL
(	NULL
Eu-Pim1	NULL
,	NULL
van	NULL
Lohuizen	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
)	NULL
.	NULL

CD2-Runx2/Eu-Pim1	NULL
animals	NULL
displayed	NULL
a	NULL
significant	NULL
increase	NULL
in	NULL
the	NULL
rate	NULL
of	NULL
tumour	NULL
onset	NULL
when	NULL
compared	NULL
with	NULL
either	NULL
CD2-Runx	NULL
?	NULL

2	NULL
(	NULL
P	NULL
<	NULL
0.005	NULL
)	NULL
or	NULL
Eu-Piml	NULL
(	NULL
P	NULL
<	NULL
0.001	NULL
)	NULL
littermate	NULL
controls	NULL
(	NULL
Figure	NULL
3b	NULL
)	NULL
.	NULL

Seventy-six	NULL
per	NULL
cent	NULL
(	NULL
19/25	NULL
)	NULL
of	NULL
double	NULL
transgenic	NULL
animals	NULL
succumbed	NULL
with	NULL
spontaneous	NULL
T-cell	NULL
lymphoma	NULL
by	NULL
250	NULL
days	NULL
of	NULL
age	NULL
compared	NULL
to	NULL
only	NULL
23	NULL
%	NULL
(	NULL
9/40	NULL
)	NULL
of	NULL
littermate	NULL
mice	NULL
with	NULL
a	NULL
CD2-Runx2	NULL
?	NULL

transgene	NULL
.	NULL

It	NULL
is	NULL
noteworthy	NULL
that	NULL
the	NULL
introduction	NULL
of	NULL
the	NULL
FVB	NULL
tumour	NULL
susceptible	NULL
strain	NULL
altered	NULL
tumour	NULL
incidence	NULL
in	NULL
mice	NULL
with	NULL
a	NULL
CD2-Runx2	NULL
transgene	NULL
from	NULL
7	NULL
to	NULL
23	NULL
%	NULL
(	NULL
Vaillant	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1999	NULL
)	NULL
(	NULL
Figure	NULL
3b	NULL
)	NULL
.	NULL

To	NULL
exclude	NULL
the	NULL
possibility	NULL
that	NULL
modifying	NULL
genes	NULL
were	NULL
influencing	NULL
tumour	NULL
incidence	NULL
in	NULL
CD2-Runx2/Epu-Piml	NULL
double	NULL
transgenic	NULL
mice	NULL
,	NULL
all	NULL
controls	NULL
were	NULL
strain-matched	NULL
first	NULL
generation	NULL
littermate	NULL
animals	NULL
.	NULL

None	NULL
of	NULL
the	NULL
twelve	NULL
Ep-Pim1	NULL
littermates	NULL
developed	NULL
lymphoma	NULL
within	NULL
the	NULL
study	NULL
period	NULL
.	NULL

Post	NULL
mortem	NULL
revealed	NULL
enlargement	NULL
of	NULL
the	NULL
thymus	NULL
with	NULL
extensive	NULL
involvement	NULL
of	NULL
other	NULL
lymphoid	NULL
tissues	NULL
including	NULL
spleen	NULL
,	NULL
and	NULL
subcutaneous	NULL
and	NULL
mesen-teric	NULL
lymph	NULL
nodes	NULL
reflecting	NULL
the	NULL
disease	NULL
spectrum	NULL
of	NULL
the	NULL
CD2-Runx2	NULL
?	NULL

transgenic	NULL
mice	NULL
.	NULL

Although	NULL
the	NULL
acceleration	NULL
in	NULL
onset	NULL
of	NULL
tumour	NULL
formation	NULL
was	NULL
not	NULL
as	NULL
dramatic	NULL
as	NULL
that	NULL
observed	NULL
in	NULL
the	NULL
Moloney	NULL
MLV-infected	NULL
CD2-Runx2	NULL
or	NULL
CD2-Runx2/p53	NULL
--	NULL
mice	NULL
,	NULL
this	NULL
result	NULL
demonstrates	NULL
the	NULL
ability	NULL
of	NULL
Runx2	NULL
to	NULL
independently	NULL
synergise	NULL
with	NULL
a	NULL
Piml	NULL
oncogene	NULL
.	NULL

This	NULL
finding	NULL
was	NULL
further	NULL
confirmed	NULL
by	NULL
the	NULL
generation	NULL
of	NULL
a	NULL
cohort	NULL
of	NULL
16	NULL
mice	NULL
triple	NULL
positive	NULL
for	NULL
the	NULL
CD2-Runx2	NULL
,	NULL
CD2-MYC	NULL
and	NULL
Ep-Pim1	NULL
transgenes	NULL
.	NULL

These	NULL
animals	NULL
died	NULL
significantly	NULL
faster	NULL
(	NULL
P	NULL
<	NULL
0.05	NULL
)	NULL
than	NULL
CD2-Runx2/CD2-MYC	NULL
,	NULL
CD2-MYC/	NULL
Epu-Pim1	NULL
or	NULL
CD2-Runx2/Epu-Pim1	NULL
littermate	NULL
transgenic	NULL
animals	NULL
(	NULL
Figure	NULL
4	NULL
)	NULL
.	NULL

Together	NULL
these	NULL
results	NULL
clearly	NULL
demonstrate	NULL
that	NULL
Runx	NULL
?	NULL

can	NULL
act	NULL
as	NULL
a	NULL
dominant	NULL
oncogene	NULL
contributing	NULL
uniquely	NULL
to	NULL
the	NULL
oncogenic	NULL
process	NULL
and	NULL
again	NULL
support	NULL
the	NULL
placement	NULL
of	NULL
Runx2	NULL
in	NULL
a	NULL
novel	NULL
gene	NULL
complementation	NULL
group	NULL
.	NULL

Thymic	NULL
tumours	NULL
from	NULL
CD2-Runx2/p53	NULL
--	NULL
,	NULL
CD2-Runx2/	NULL
Eu-Pim1	NULL
and	NULL
CD2-Runx2/MYC/Ep-Pim1	NULL
crosses	NULL
display	NULL
a	NULL
consistent	NULL
T-cell	NULL
phenotype	NULL
Cells	NULL
prepared	NULL
from	NULL
thymus	NULL
were	NULL
analysed	NULL
by	NULL
flow	NULL
cytometry	NULL
for	NULL
the	NULL
expression	NULL
of	NULL
cell	NULL
surface	NULL
antigens	NULL
CD3/CD45R	NULL
and	NULL
CD4/CD8	NULL
.	NULL

The	NULL
cells	NULL
of	NULL
all	NULL
tumours	NULL
analysed	NULL
were	NULL
CD3*/CD45R-	NULL
confirming	NULL
their	NULL
T-cell	NULL
-	NULL
#	NULL
-	NULL
Runx2	NULL
MYC	NULL
iPim1t	NULL
O-	NULL
Runx2IMYC	NULL
-¥-	NULL
Runx2	NULL
iPimt	NULL
-v-	NULL
MYCiPim1t	NULL
%	NULL
tumour	NULL
free	NULL
survival	NULL
``	NULL
o	NULL
,	NULL
On	NULL
.	NULL

``	NULL
o	NULL
0	NULL
-	NULL
r	NULL
+	NULL
m	NULL
a-	NULL
i	NULL
&	NULL
20	NULL
25	NULL
30	NULL
35	NULL
40	NULL
45	NULL
50	NULL
Time	NULL
(	NULL
days	NULL
)	NULL
Figure	NULL
4	NULL
Genetic	NULL
complementation	NULL
in	NULL
animals	NULL
with	NULL
three	NULL
transgenes	NULL
.	NULL

Lymphoma	NULL
free	NULL
survival	NULL
is	NULL
shown	NULL
for	NULL
transgenic	NULL
animals	NULL
which	NULL
simultaneously	NULL
carry	NULL
CD2-Runx2	NULL
,	NULL
CD2-MYC	NULL
and	NULL
Eu-Pim1	NULL
transgenes	NULL
(	NULL
filled	NULL
circles	NULL
,	NULL
»	NULL
=16	NULL
)	NULL
.	NULL

These	NULL
animals	NULL
die	NULL
significantly	NULL
faster	NULL
than	NULL
those	NULL
animals	NULL
with	NULL
two	NULL
transgenes	NULL
;	NULL
CD2-Runx2/CD2-MYC	NULL
(	NULL
open	NULL
circles	NULL
,	NULL
n=50	NULL
)	NULL
,	NULL
CD2-Runx2/Eu-Pim1l	NULL
(	NULL
filled	NULL
triangles	NULL
,	NULL
»	NULL
=29	NULL
)	NULL
and	NULL
CD2-MYC/Eu-pim1	NULL
(	NULL
open	NULL
triangles	NULL
,	NULL
n=10	NULL
)	NULL
origin	NULL
.	NULL

The	NULL
results	NULL
of	NULL
the	NULL
CD4/CD8	NULL
analysis	NULL
are	NULL
summarised	NULL
in	NULL
Table	NULL
1	NULL
and	NULL
Figure	NULL
5	NULL
.	NULL

Fifteen	NULL
CD2-Runx2	NULL
?	NULL

/p53-~-	NULL
tumours	NULL
were	NULL
analysed	NULL
.	NULL

All	NULL
displayed	NULL
a	NULL
consistent	NULL
CD8*	NULL
,	NULL
CD4-+	NULL
phenotype	NULL
.	NULL

This	NULL
was	NULL
also	NULL
observed	NULL
in	NULL
four	NULL
CD2-Runx2/p53-*	NULL
tumours	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
and	NULL
contrasts	NULL
with	NULL
the	NULL
more	NULL
variable	NULL
phenotype	NULL
observed	NULL
in	NULL
thymocytes	NULL
from	NULL
p53	NULL
null	NULL
and	NULL
p53	NULL
heterozygote	NULL
tumours	NULL
(	NULL
Blyth	NULL
,	NULL
1996	NULL
)	NULL
.	NULL

A	NULL
similar	NULL
cell	NULL
surface	NULL
phenotype	NULL
was	NULL
identified	NULL
in	NULL
four	NULL
CD2-Runx2/	NULL
Epu-Piml	NULL
and	NULL
four	NULL
CD2-Runx2/MYC/Epu-Piml	NULL
tumours	NULL
analysed	NULL
and	NULL
contrasts	NULL
with	NULL
the	NULL
phenotypes	NULL
reported	NULL
for	NULL
tumours	NULL
arising	NULL
in	NULL
CD2-MYC	NULL
transgenic	NULL
mice	NULL
(	NULL
Stewart	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
,	NULL
and	NULL
in	NULL
Eu-Pim1	NULL
transgenic	NULL
mice	NULL
which	NULL
display	NULL
a	NULL
skew	NULL
to	NULL
CD4	NULL
SP	NULL
thymocytes	NULL
(	NULL
van	NULL
Lohuizen	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
)	NULL
.	NULL

The	NULL
transformed	NULL
populations	NULL
observed	NULL
in	NULL
all	NULL
of	NULL
the	NULL
CD2-Runx	NULL
?	NULL

transgenic	NULL
crosses	NULL
reflect	NULL
the	NULL
skewed	NULL
thymocyte	NULL
phenotype	NULL
reported	NULL
in	NULL
pre-neoplastic	NULL
thymocytes	NULL
prepared	NULL
from	NULL
CD2-Runx2	NULL
transgenic	NULL
animals	NULL
(	NULL
Vaillant	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1999	NULL
)	NULL
and	NULL
demonstrate	NULL
the	NULL
dominant	NULL
effect	NULL
of	NULL
Runx2	NULL
on	NULL
the	NULL
tumour	NULL
cell	NULL
phenotype	NULL
.	NULL

Discussion	NULL
Our	NULL
previous	NULL
studies	NULL
have	NULL
shown	NULL
that	NULL
Runx2	NULL
over-expression	NULL
in	NULL
the	NULL
T-cell	NULL
compartment	NULL
predisposes	NULL
to	NULL
lymphoma	NULL
development	NULL
and	NULL
is	NULL
strongly	NULL
synergistic	NULL
with	NULL
MYC	NULL
(	NULL
Vaillant	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1999	NULL
)	NULL
.	NULL

This	NULL
study	NULL
confirms	NULL
and	NULL
extends	NULL
these	NULL
observations	NULL
and	NULL
shows	NULL
that	NULL
the	NULL
gene	NULL
is	NULL
independently	NULL
synergistic	NULL
with	NULL
a	NULL
Piml	NULL
oncogene	NULL
and	NULL
with	NULL
the	NULL
p53	NULL
null	NULL
genotype	NULL
.	NULL

Moloney	NULL
MLV-induced	NULL
lymphomas	NULL
were	NULL
also	NULL
found	NULL
to	NULL
be	NULL
accelerated	NULL
in	NULL
Runx2	NULL
transgenic	NULL
mice	NULL
and	NULL
analysis	NULL
of	NULL
proviral	NULL
insertion	NULL
sites	NULL
in	NULL
these	NULL
lymphomas	NULL
revealed	NULL
frequent	NULL
hits	NULL
at	NULL
loci	NULL
representing	NULL
each	NULL
of	NULL
three	NULL
previously	NULL
established	NULL
Runx2	NULL
,	NULL
in	NULL
vivo	NULL
complementation	NULL
and	NULL
retroviral	NULL
tagging	NULL
K	NULL
Blyth	NULL
et	NULL
al	NULL
15.0	NULL
%	NULL
73.1	NULL
%	NULL
$	NULL
0.0	NULL
%	NULL
169	NULL
%	NULL
CD4	NULL
lhe	NULL
=	NULL
Is	NULL
=	NULL
he	NULL
Oms	NULL
¥	NULL
CD8	NULL
Figure	NULL
5	NULL
Analysis	NULL
of	NULL
CD4	NULL
and	NULL
CD8	NULL
surface	NULL
expression	NULL
of	NULL
tumour	NULL
cells	NULL
from	NULL
(	NULL
a	NULL
)	NULL
CD2-Runx2	NULL
,	NULL
(	NULL
b	NULL
)	NULL
CD2-Runx2/p353	NULL
null	NULL
,	NULL
(	NULL
c	NULL
)	NULL
CD2-Runx2/Eu-pim1	NULL
,	NULL
(	NULL
d	NULL
)	NULL
CD2-Runx2/MYC/Eu-Pim1	NULL
transgenic	NULL
mice	NULL
and	NULL
(	NULL
e	NULL
)	NULL
thymocytes	NULL
from	NULL
healthy	NULL
non-transgenic	NULL
thymus	NULL
.	NULL

Data	NULL
from	NULL
one	NULL
representative	NULL
for	NULL
each	NULL
of	NULL
the	NULL
above	NULL
groups	NULL
of	NULL
mice	NULL
is	NULL
shown	NULL
.	NULL

Cells	NULL
were	NULL
labelled	NULL
with	NULL
PE	NULL
or	NULL
QR	NULL
anti-CD4	NULL
and	NULL
FITC	NULL
anti-CD8	NULL
monoclonal	NULL
antibodies	NULL
complementation	NULL
groups	NULL
(	NULL
Berns	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1999	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
proviral	NULL
insertions	NULL
at	NULL
c-Myc	NULL
or	NULL
N-Mye	NULL
were	NULL
significantly	NULL
more	NULL
common	NULL
in	NULL
tumours	NULL
of	NULL
Runx2	NULL
transgenic	NULL
mice	NULL
than	NULL
in	NULL
controls	NULL
,	NULL
suggesting	NULL
that	NULL
the	NULL
Runx2/Mye	NULL
combination	NULL
confers	NULL
a	NULL
particular	NULL
selective	NULL
advantage	NULL
.	NULL

Together	NULL
,	NULL
these	NULL
results	NULL
indicate	NULL
that	NULL
Runx2	NULL
has	NULL
a	NULL
novel	NULL
oncogenic	NULL
function	NULL
with	NULL
is	NULL
strongly	NULL
selected	NULL
in	NULL
the	NULL
context	NULL
of	NULL
Myc	NULL
over-expression	NULL
.	NULL

Phenotypic	NULL
analysis	NULL
of	NULL
tumours	NULL
from	NULL
CD2-Runx2	NULL
mice	NULL
revealed	NULL
a	NULL
highly	NULL
consistent	NULL
surface	NULL
phenotype	NULL
which	NULL
was	NULL
similar	NULL
to	NULL
an	NULL
expanded	NULL
cell	NULL
population	NULL
seen	NULL
in	NULL
pre-lymphomatous	NULL
transgenic	NULL
mice	NULL
(	NULL
Vaillant	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1999	NULL
)	NULL
,	NULL
with	NULL
cells	NULL
expressing	NULL
high	NULL
levels	NULL
of	NULL
CD8	NULL
and	NULL
a	NULL
spectrum	NULL
of	NULL
CD4	NULL
levels	NULL
.	NULL

Intriguingly	NULL
,	NULL
a	NULL
similar	NULL
phenotype	NULL
was	NULL
also	NULL
seen	NULL
in	NULL
tumours	NULL
arising	NULL
in	NULL
Moloney	NULL
MLV	NULL
infected	NULL
Runx2	NULL
transgenics	NULL
and	NULL
in	NULL
Runx2	NULL
mice	NULL
crossed	NULL
with	NULL
Pim	NULL
!	NULL

transgenic	NULL
or	NULL
p53	NULL
null	NULL
mice	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
tumours	NULL
arising	NULL
in	NULL
Moloney	NULL
MLV	NULL
infected	NULL
wild-type	NULL
or	NULL
in	NULL
p53	NULL
null	NULL
mice	NULL
normally	NULL
show	NULL
a	NULL
heterogeneous	NULL
range	NULL
of	NULL
phenotypes	NULL
(	NULL
Clark	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
;	NULL
Lazo	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
;	NULL
Blyth	NULL
,	NULL
1996	NULL
)	NULL
while	NULL
spontaneous	NULL
299	NULL
Oncogene	NULL
Runx2	NULL
,	NULL
in	NULL
vivo	NULL
complementation	NULL
and	NULL
retroviral	NULL
tagging	NULL
K	NULL
Blyth	NULL
et	NULL
al	NULL
300	NULL
tumours	NULL
in	NULL
Epu-Piml	NULL
transgenic	NULL
mice	NULL
tend	NULL
to	NULL
be	NULL
immature	NULL
(	NULL
van	NULL
Lohuizen	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
)	NULL
.	NULL

These	NULL
results	NULL
demonstrate	NULL
a	NULL
strongly	NULL
dominant	NULL
effect	NULL
of	NULL
Runx2	NULL
on	NULL
the	NULL
tumour	NULL
cell	NULL
phenotype	NULL
.	NULL

The	NULL
possibility	NULL
that	NULL
Runx2	NULL
directly	NULL
regulates	NULL
the	NULL
expression	NULL
of	NULL
this	NULL
phenotypic	NULL
programme	NULL
is	NULL
currently	NULL
under	NULL
investigation	NULL
.	NULL

Alterna-tively	NULL
,	NULL
the	NULL
Runx2	NULL
oncogene	NULL
may	NULL
select	NULL
for	NULL
the	NULL
transformation	NULL
of	NULL
cells	NULL
at	NULL
a	NULL
specific	NULL
stage	NULL
in	NULL
T-cell	NULL
differentiation	NULL
.	NULL

Indeed	NULL
,	NULL
preliminary	NULL
experiments	NULL
indicate	NULL
that	NULL
the	NULL
increased	NULL
proportion	NULL
of	NULL
CD8	NULL
SP	NULL
cells	NULL
in	NULL
normal	NULL
CD2-Runx2	NULL
thymocytes	NULL
results	NULL
from	NULL
the	NULL
expansion	NULL
of	NULL
the	NULL
immature	NULL
CD8	NULL
SP	NULL
population	NULL
(	NULL
CD4-	NULL
,	NULL
CD8+	NULL
,	NULL
HSA*	NULL
,	NULL
TCR-*°	NULL
cells	NULL
preceding	NULL
the	NULL
CD4CDS®	NULL
DP	NULL
stage	NULL
)	NULL
.	NULL

Transformation	NULL
of	NULL
cells	NULL
from	NULL
this	NULL
enlarged	NULL
population	NULL
could	NULL
lead	NULL
to	NULL
the	NULL
phenotype	NULL
presented	NULL
in	NULL
this	NULL
report	NULL
.	NULL

The	NULL
over-representation	NULL
of	NULL
proviral	NULL
insertions	NULL
at	NULL
c-Myce	NULL
or	NULL
N-Myce	NULL
in	NULL
Moloney	NULL
MLV	NULL
infected	NULL
CD2-Runx2	NULL
mice	NULL
is	NULL
intriguing	NULL
and	NULL
shows	NULL
a	NULL
close	NULL
parallel	NULL
with	NULL
previous	NULL
observations	NULL
on	NULL
Epu-Piml	NULL
transgenic	NULL
mice	NULL
in	NULL
which	NULL
retroviral	NULL
infection	NULL
leads	NULL
to	NULL
rapid	NULL
tumour	NULL
onset	NULL
with	NULL
a	NULL
high	NULL
frequency	NULL
of	NULL
insertion	NULL
at	NULL
Myc	NULL
family	NULL
genes	NULL
(	NULL
van	NULL
Lohuizen	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
)	NULL
.	NULL

How	NULL
does	NULL
this	NULL
selection	NULL
operate	NULL
?	NULL

It	NULL
seems	NULL
unlikely	NULL
that	NULL
the	NULL
Runx2	NULL
gene	NULL
directly	NULL
affects	NULL
the	NULL
frequency	NULL
of	NULL
proviral	NULL
insertion	NULL
at	NULL
Myc	NULL
family	NULL
genes	NULL
and	NULL
in	NULL
accord	NULL
with	NULL
this	NULL
view	NULL
we	NULL
found	NULL
no	NULL
evidence	NULL
of	NULL
an	NULL
increased	NULL
proviral	NULL
copy	NULL
number	NULL
in	NULL
Runx	NULL
?	NULL

transgenic	NULL
tumours	NULL
compared	NULL
to	NULL
controls	NULL
.	NULL

A	NULL
more	NULL
plausible	NULL
explanation	NULL
is	NULL
that	NULL
cells	NULL
which	NULL
acquire	NULL
proviral	NULL
insertions	NULL
at	NULL
Myc	NULL
genes	NULL
are	NULL
favoured	NULL
for	NULL
outgrowth	NULL
in	NULL
Runx2	NULL
transgenic	NULL
mice	NULL
.	NULL

One	NULL
possibility	NULL
is	NULL
that	NULL
over-expressed	NULL
Runx2	NULL
transactivates	NULL
the	NULL
Moloney	NULL
MLV	NULL
LTR	NULL
enhancer	NULL
,	NULL
increasing	NULL
the	NULL
effects	NULL
of	NULL
proviral	NULL
insertion	NULL
near	NULL
a	NULL
Myc	NULL
family	NULL
gene	NULL
.	NULL

In	NULL
favour	NULL
of	NULL
this	NULL
model	NULL
,	NULL
the	NULL
Moloney	NULL
MLV	NULL
LTR	NULL
core	NULL
enhancer	NULL
contains	NULL
critically	NULL
important	NULL
binding	NULL
sites	NULL
for	NULL
CBF	NULL
(	NULL
Zaiman	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

However	NULL
,	NULL
it	NULL
should	NULL
be	NULL
noted	NULL
that	NULL
this	NULL
hypothesis	NULL
would	NULL
not	NULL
account	NULL
for	NULL
the	NULL
powerful	NULL
synergy	NULL
between	NULL
Myc	NULL
and	NULL
Runx2	NULL
transgenes	NULL
when	NULL
combined	NULL
in	NULL
the	NULL
germline	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
the	NULL
exogenous	NULL
viral	NULL
cofactor	NULL
(	NULL
Vaillant	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1999	NULL
)	NULL
.	NULL

An	NULL
alternative	NULL
hypothesis	NULL
is	NULL
that	NULL
the	NULL
strong	NULL
selection	NULL
for	NULL
insertions	NULL
at	NULL
Myc	NULL
family	NULL
genes	NULL
operates	NULL
by	NULL
enhanced	NULL
survival	NULL
or	NULL
growth	NULL
of	NULL
cells	NULL
over-expressing	NULL
these	NULL
key	NULL
genes	NULL
as	NULL
a	NULL
result	NULL
of	NULL
proviral	NULL
insertion	NULL
.	NULL

In	NULL
favour	NULL
of	NULL
this	NULL
idea	NULL
,	NULL
we	NULL
have	NULL
noted	NULL
that	NULL
expression	NULL
of	NULL
the	NULL
CD2-MYC	NULL
transgene	NULL
,	NULL
which	NULL
is	NULL
normally	NULL
undetectable	NULL
in	NULL
the	NULL
thymus	NULL
of	NULL
prelymphomatous	NULL
mice	NULL
,	NULL
is	NULL
highly	NULL
expressed	NULL
when	NULL
combined	NULL
with	NULL
a	NULL
CD2-Runx2	NULL
gene	NULL
and	NULL
we	NULL
have	NULL
suggested	NULL
that	NULL
this	NULL
phenomenon	NULL
is	NULL
due	NULL
to	NULL
enhanced	NULL
survival	NULL
of	NULL
CD2-MYC	NULL
expressing	NULL
T-cells	NULL
in	NULL
vivo	NULL
(	NULL
Vaillant	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1999	NULL
)	NULL
.	NULL

However	NULL
,	NULL
if	NULL
Runx2	NULL
acts	NULL
by	NULL
abrogation	NULL
of	NULL
Myc-induced	NULL
apoptosis	NULL
,	NULL
this	NULL
would	NULL
appear	NULL
to	NULL
be	NULL
dependent	NULL
on	NULL
the	NULL
in	NULL
vivo	NULL
context	NULL
as	NULL
we	NULL
also	NULL
found	NULL
that	NULL
Runx2	NULL
was	NULL
unable	NULL
to	NULL
prevent	NULL
apoptosis	NULL
induced	NULL
by	NULL
a	NULL
regulatable	NULL
form	NULL
of	NULL
Myc	NULL
(	NULL
CD2-MYC-ER	NULL
``	NULL
)	NULL
in	NULL
lines	NULL
established	NULL
directly	NULL
from	NULL
tumours	NULL
(	NULL
Vaillant	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1999	NULL
;	NULL
Blyth	NULL
et	NULL
al	NULL
.	NULL

,	NULL
2000	NULL
)	NULL
.	NULL

In	NULL
a	NULL
similar	NULL
fashion	NULL
,	NULL
the	NULL
critical	NULL
oncogenic	NULL
function	NULL
of	NULL
the	NULL
Pim1l	NULL
kinase	NULL
has	NULL
not	NULL
been	NULL
defined	NULL
clearly	NULL
but	NULL
an	NULL
anti-apoptotic	NULL
role	NULL
has	NULL
been	NULL
noted	NULL
in	NULL
some	NULL
studies	NULL
(	NULL
Lilly	NULL
Oncogene	NULL
and	NULL
Kraft	NULL
,	NULL
1997	NULL
;	NULL
Leverson	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998	NULL
;	NULL
Lilly	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1999	NULL
;	NULL
Shirogane	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1999	NULL
)	NULL
while	NULL
others	NULL
have	NULL
suggested	NULL
that	NULL
Pim1	NULL
acts	NULL
to	NULL
amplify	NULL
Myc	NULL
signalling	NULL
in	NULL
a	NULL
pro-apoptotic	NULL
manner	NULL
(	NULL
Mochizuki	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1997	NULL
,	NULL
1999	NULL
)	NULL
.	NULL

Irrespective	NULL
of	NULL
the	NULL
mechanism	NULL
by	NULL
which	NULL
they	NULL
confer	NULL
selective	NULL
advantage	NULL
on	NULL
the	NULL
Myc-expressing	NULL
cell	NULL
,	NULL
it	NULL
is	NULL
clear	NULL
that	NULL
Runx2	NULL
and	NULL
Piml	NULL
are	NULL
not	NULL
functionally	NULL
redundant	NULL
.	NULL

Indeed	NULL
,	NULL
this	NULL
study	NULL
shows	NULL
that	NULL
the	NULL
genes	NULL
are	NULL
synergistic	NULL
when	NULL
combined	NULL
in	NULL
the	NULL
germline	NULL
and	NULL
that	NULL
proviral	NULL
insertions	NULL
at	NULL
Pim	NULL
family	NULL
genes	NULL
occur	NULL
with	NULL
similar	NULL
frequency	NULL
in	NULL
Runx2	NULL
transgenic	NULL
and	NULL
control	NULL
mice	NULL
.	NULL

We	NULL
can	NULL
also	NULL
conclude	NULL
that	NULL
Runx2	NULL
and	NULL
p53	NULL
are	NULL
functionally	NULL
distinct	NULL
Myc	NULL
collaborators	NULL
as	NULL
Runx2	NULL
and	NULL
p53	NULL
loss	NULL
are	NULL
powerfully	NULL
synergistic	NULL
in	NULL
vivo	NULL
.	NULL

Moloney	NULL
MLV	NULL
insertions	NULL
were	NULL
also	NULL
observed	NULL
at	NULL
the	NULL
Pall/Gfil	NULL
locus	NULL
in	NULL
Runx2	NULL
transgenic	NULL
mice	NULL
.	NULL

Although	NULL
a	NULL
lower	NULL
hit	NULL
rate	NULL
was	NULL
evident	NULL
in	NULL
transgenic	NULL
mice	NULL
compared	NULL
to	NULL
controls	NULL
(	NULL
18	NULL
%	NULL
vs	NULL
33	NULL
%	NULL
)	NULL
this	NULL
difference	NULL
was	NULL
not	NULL
statistically	NULL
significant	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
Runx	NULL
?	NULL

is	NULL
not	NULL
functionally	NULL
redundant	NULL
with	NULL
Gil	NULL
,	NULL
the	NULL
presumptive	NULL
target	NULL
of	NULL
insertions	NULL
at	NULL
these	NULL
loci	NULL
(	NULL
Scheijen	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1997	NULL
)	NULL
.	NULL

However	NULL
,	NULL
a	NULL
surprising	NULL
feature	NULL
of	NULL
this	NULL
cohort	NULL
was	NULL
the	NULL
absence	NULL
of	NULL
tumours	NULL
with	NULL
insertions	NULL
at	NULL
both	NULL
Pim	NULL
family	NULL
genes	NULL
and	NULL
at	NULL
Pa/ll/Gfil	NULL
.	NULL

Only	NULL
one	NULL
candidate	NULL
was	NULL
noted	NULL
out	NULL
of	NULL
44	NULL
transgenic	NULL
mouse	NULL
tumours	NULL
and	NULL
this	NULL
was	NULL
an	NULL
oligoclonal	NULL
tumour	NULL
in	NULL
which	NULL
it	NULL
was	NULL
clear	NULL
that	NULL
distinct	NULL
clones	NULL
carried	NULL
each	NULL
insertion	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
studies	NULL
on	NULL
Eu-Myc	NULL
,	NULL
Pim1	NULL
,	NULL
and	NULL
Lck-Gfil	NULL
transgenic	NULL
mice	NULL
which	NULL
defined	NULL
three	NULL
complementation	NULL
groups	NULL
(	NULL
Myce	NULL
,	NULL
Pim	NULL
and	NULL
Bmi/Gfi	NULL
)	NULL
on	NULL
the	NULL
basis	NULL
of	NULL
their	NULL
reciprocal	NULL
activation	NULL
pattern	NULL
showed	NULL
a	NULL
high	NULL
prevalence	NULL
of	NULL
tumours	NULL
involving	NULL
members	NULL
of	NULL
each	NULL
group	NULL
(	NULL
Scheijen	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1997	NULL
;	NULL
Schmidt	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998	NULL
;	NULL
Berns	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1999	NULL
)	NULL
.	NULL

This	NULL
pattern	NULL
of	NULL
complementation	NULL
appears	NULL
to	NULL
break	NULL
down	NULL
in	NULL
Runx2	NULL
transgenic	NULL
mice	NULL
where	NULL
either	NULL
Pim	NULL
or	NULL
Pal/Gfi	NULL
genes	NULL
are	NULL
targeted	NULL
in	NULL
addition	NULL
to	NULL
Myc	NULL
.	NULL

Recent	NULL
evidence	NULL
suggests	NULL
that	NULL
Myc	NULL
over-expression	NULL
,	NULL
besides	NULL
signalling	NULL
proliferation	NULL
,	NULL
renders	NULL
cells	NULL
sensitive	NULL
to	NULL
death	NULL
by	NULL
multiple	NULL
effector	NULL
pathways	NULL
.	NULL

It	NULL
is	NULL
widely	NULL
assumed	NULL
that	NULL
tumours	NULL
induced	NULL
by	NULL
Myc	NULL
must	NULL
acquire	NULL
resistance	NULL
to	NULL
its	NULL
apoptotic	NULL
effects	NULL
(	NULL
reviewed	NULL
in	NULL
Pren-dergast	NULL
,	NULL
1999	NULL
)	NULL
.	NULL

However	NULL
,	NULL
this	NULL
assumption	NULL
is	NULL
challenged	NULL
by	NULL
the	NULL
observations	NULL
that	NULL
Myc-induced	NULL
tumours	NULL
can	NULL
expand	NULL
despite	NULL
a	NULL
high	NULL
apoptotic	NULL
index	NULL
(	NULL
Blyth	NULL
,	NULL
1996	NULL
)	NULL
and	NULL
that	NULL
spontaneous	NULL
tumours	NULL
arising	NULL
in	NULL
mice	NULL
carrying	NULL
a	NULL
regulatable	NULL
form	NULL
of	NULL
MYC	NULL
retain	NULL
the	NULL
capacity	NULL
to	NULL
undergo	NULL
apoptosis	NULL
on	NULL
MYC	NULL
activation	NULL
(	NULL
Blyth	NULL
et	NULL
al	NULL
.	NULL

,	NULL
2000	NULL
)	NULL
.	NULL

A	NULL
possible	NULL
rationale	NULL
for	NULL
these	NULL
apparently	NULL
contradictory	NULL
observations	NULL
is	NULL
that	NULL
the	NULL
resistance	NULL
of	NULL
tumour	NULL
cells	NULL
to	NULL
Myc-induced	NULL
apoptosis	NULL
is	NULL
only	NULL
relative	NULL
and	NULL
that	NULL
tumour	NULL
outgrowth	NULL
will	NULL
occur	NULL
upon	NULL
inactivation	NULL
or	NULL
suppression	NULL
of	NULL
a	NULL
subset	NULL
of	NULL
the	NULL
death	NULL
pathways	NULL
induced	NULL
by	NULL
ectopic	NULL
Myc	NULL
expression	NULL
.	NULL

According	NULL
to	NULL
this	NULL
model	NULL
,	NULL
the	NULL
activation	NULL
of	NULL
any	NULL
two	NULL
of	NULL
the	NULL
Runx	NULL
,	NULL
Pim	NULL
or	NULL
Gfil	NULL
genes	NULL
may	NULL
be	NULL
sufficient	NULL
to	NULL
reduce	NULL
the	NULL
apoptotic	NULL
effects	NULL
of	NULL
Myc	NULL
below	NULL
a	NULL
threshold	NULL
required	NULL
for	NULL
tumour	NULL
outgrowth	NULL
.	NULL

A	NULL
quantitative	NULL
model	NULL
of	NULL
this	NULL
type	NULL
could	NULL
account	NULL
for	NULL
the	NULL
apparent	NULL
breakdown	NULL
of	NULL
previously	NULL
observed	NULL
complementation	NULL
patterns	NULL
in	NULL
Runx2	NULL
transgenic	NULL
mice	NULL
.	NULL

To	NULL
test	NULL
this	NULL
model	NULL
further	NULL
,	NULL
it	NULL
will	NULL
be	NULL
important	NULL
to	NULL
elucidate	NULL
the	NULL
gene	NULL
programmes	NULL
perturbed	NULL
by	NULL
Runx2	NULL
over-expression	NULL
and	NULL
establish	NULL
their	NULL
relationship	NULL
to	NULL
the	NULL
pathways	NULL
activated	NULL
by	NULL
Myc	NULL
and	NULL
the	NULL
other	NULL
Myc-collaborating	NULL
genes	NULL
.	NULL

Materials	NULL
and	NULL
methods	NULL
Transgenic	NULL
animals	NULL
The	NULL
CD2-Runx2	NULL
transgenic	NULL
mice	NULL
were	NULL
generated	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
Vaillant	NULL
er	NULL
a/	NULL
.	NULL

,	NULL
1999	NULL
)	NULL
.	NULL

Newborn	NULL
CD2-Runx2	NULL
mice	NULL
and	NULL
control	NULL
littermates	NULL
were	NULL
infected	NULL
with	NULL
10°	NULL
infectious	NULL
units	NULL
of	NULL
Moloney	NULL
MLV	NULL
clone	NULL
1A	NULL
(	NULL
van	NULL
Lohuizen	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
within	NULL
24	NULL
h	NULL
of	NULL
birth	NULL
.	NULL

Genotypes	NULL
of	NULL
mice	NULL
were	NULL
identified	NULL
by	NULL
Southern	NULL
blot	NULL
hybridization	NULL
analysis	NULL
carried	NULL
out	NULL
on	NULL
DNA	NULL
extracted	NULL
after	NULL
tail	NULL
biopsy	NULL
.	NULL

CD2-Runx2	NULL
mice	NULL
were	NULL
bred	NULL
with	NULL
p53	NULL
null	NULL
mice	NULL
(	NULL
Donehower	NULL
ert	NULL
a/	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
to	NULL
generate	NULL
transgenic	NULL
mice	NULL
homozygous	NULL
null	NULL
for	NULL
the	NULL
p53	NULL
tumour	NULL
suppressor	NULL
gene	NULL
and	NULL
control	NULL
groups	NULL
.	NULL

F1	NULL
animals	NULL
heterozygous	NULL
for	NULL
both	NULL
Pim	NULL
]	NULL
and	NULL
Runx2	NULL
transgenes	NULL
,	NULL
and	NULL
littermate	NULL
controls	NULL
,	NULL
were	NULL
achieved	NULL
by	NULL
breeding	NULL
CD2-Runx2	NULL
mice	NULL
and	NULL
Eu-Pim1	NULL
transgenic	NULL
mice	NULL
(	NULL
van	NULL
Lohuizen	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
)	NULL
.	NULL

CD2-Runx2/CD2-MYC	NULL
transgenic	NULL
animals	NULL
have	NULL
been	NULL
described	NULL
previously	NULL
(	NULL
Vaillant	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1999	NULL
)	NULL
.	NULL

Triple	NULL
transgenic	NULL
animals	NULL
were	NULL
generated	NULL
by	NULL
breeding	NULL
CD2-MYC	NULL
(	NULL
Stewart	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
and	NULL
Epu-Pim1l	NULL
animals	NULL
with	NULL
subsequent	NULL
breeding	NULL
of	NULL
F1	NULL
double	NULL
transgenics	NULL
with	NULL
CD2-Runx2	NULL
mice	NULL
.	NULL

Animals	NULL
showing	NULL
signs	NULL
of	NULL
malaise	NULL
were	NULL
sacrificed	NULL
and	NULL
necropsied	NULL
.	NULL

DNA	NULL
hybridization	NULL
analysis	NULL
High	NULL
molecular	NULL
weight	NULL
DNA	NULL
from	NULL
mouse	NULL
tissues	NULL
and	NULL
radiolabelled	NULL
DNA	NULL
probes	NULL
were	NULL
prepared	NULL
as	NULL
previously	NULL
References	NULL
Adams	NULL
JM	NULL
,	NULL
Harris	NULL
AW	NULL
,	NULL
Pinkert	NULL
LM	NULL
,	NULL
Corcoran	NULL
LM	NULL
,	NULL
Alexander	NULL
WS	NULL
,	NULL
Cory	NULL
S	NULL
,	NULL
Palmiter	NULL
RD	NULL
and	NULL
Brinster	NULL
RL	NULL
.	NULL

(	NULL
1985	NULL
)	NULL
.	NULL

Nature	NULL
,	NULL
318	NULL
,	NULL
533-538	NULL
.	NULL

Alkema	NULL
MJ	NULL
,	NULL
Jacobs	NULL
H	NULL
,	NULL
van	NULL
Lohuizen	NULL
M	NULL
and	NULL
Berns	NULL
A	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
.	NULL

Oncogene	NULL
,	NULL
15	NULL
,	NULL
899-910	NULL
.	NULL

Baxter	NULL
EW	NULL
,	NULL
Blyth	NULL
K	NULL
,	NULL
Donehower	NULL
LA	NULL
,	NULL
Cameron	NULL
ER	NULL
,	NULL
Onions	NULL
DE	NULL
and	NULL
Neil	NULL
JC	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
.	NULL

J	NULL
.	NULL

Virol	NULL
.	NULL

,	NULL
70	NULL
,	NULL
2095-2100	NULL
.	NULL

Berns	NULL
A	NULL
,	NULL
Mikkers	NULL
H	NULL
,	NULL
Krimpenfort	NULL
P	NULL
,	NULL
Allen	NULL
J	NULL
,	NULL
Scheijen	NULL
B	NULL
and	NULL
Jonkers	NULL
J	NULL
.	NULL

(	NULL
1999	NULL
)	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
59	NULL
,	NULL
1773s-	NULL
1777s	NULL
.	NULL

Blyth	NULL
K	NULL
,	NULL
Terry	NULL
A	NULL
,	NULL
O'Hara	NULL
M	NULL
,	NULL
Baxter	NULL
EW	NULL
,	NULL
Campbell	NULL
M	NULL
,	NULL
Stewart	NULL
M	NULL
,	NULL
Donehower	NULL
L	NULL
,	NULL
Onions	NULL
DE	NULL
,	NULL
Neil	NULL
JC	NULL
and	NULL
Cameron	NULL
ER	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
.	NULL

Oncogene	NULL
,	NULL
10	NULL
,	NULL
1717-1723	NULL
.	NULL

Blyth	NULL
K.	NULL
(	NULL
1996	NULL
)	NULL
.	NULL

Ph.D	NULL
Thesis	NULL
,	NULL
University	NULL
of	NULL
Glasgow	NULL
Veterinary	NULL
School	NULL
.	NULL

A	NULL
transgenic	NULL
model	NULL
to	NULL
study	NULL
the	NULL
role	NULL
of	NULL
oncogenes	NULL
and	NULL
tumour	NULL
suppressor	NULL
genes	NULL
in	NULL
T	NULL
cell	NULL
lymphoma	NULL
.	NULL

Blyth	NULL
K	NULL
,	NULL
Stewart	NULL
M	NULL
,	NULL
Bell	NULL
M	NULL
,	NULL
James	NULL
C	NULL
,	NULL
Evan	NULL
GI	NULL
,	NULL
Neil	NULL
J	NULL
and	NULL
Cameron	NULL
ER	NULL
.	NULL

(	NULL
2000	NULL
)	NULL
.	NULL

Oncogene	NULL
,	NULL
19	NULL
,	NULL
773-782	NULL
.	NULL

Breuer	NULL
ML	NULL
,	NULL
Cuypers	NULL
HT	NULL
and	NULL
Berns	NULL
A	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
.	NULL

EMBO	NULL
J.	NULL
,	NULL
8	NULL
,	NULL
743-748	NULL
.	NULL

Clark	NULL
SS	NULL
,	NULL
Chen	NULL
E	NULL
,	NULL
Fizzotti	NULL
M	NULL
,	NULL
Witte	NULL
ON	NULL
and	NULL
Malkovska	NULL
V.	NULL
(	NULL
1993	NULL
)	NULL
.J	NULL
.	NULL

Virol	NULL
.	NULL

,	NULL
67	NULL
,	NULL
6033-6046	NULL
.	NULL

Cuypers	NULL
HT	NULL
,	NULL
Selten	NULL
G	NULL
,	NULL
Quint	NULL
W	NULL
,	NULL
Zijlstra	NULL
M	NULL
,	NULL
Maandag	NULL
ER	NULL
,	NULL
Boelens	NULL
W	NULL
,	NULL
van	NULL
Wezenbeek	NULL
P	NULL
,	NULL
Melief	NULL
C	NULL
and	NULL
Berns	NULL
A	NULL
.	NULL

(	NULL
1984	NULL
)	NULL
.	NULL

Cell	NULL
,	NULL
37	NULL
,	NULL
141-150	NULL
.	NULL

DePinho	NULL
R	NULL
and	NULL
Jacks	NULL
T	NULL
(	NULL
eds	NULL
.	NULL
)	NULL

(	NULL
1999	NULL
)	NULL
.	NULL

Oncogene	NULL
Reviews	NULL
Mouse	NULL
Models	NULL
of	NULL
Cancer	NULL
.	NULL

Stockton	NULL
Press	NULL
:	NULL
Hampshire	NULL
RG21	NULL
6XS	NULL
.	NULL

Runx2	NULL
,	NULL
in	NULL
vivo	NULL
complementation	NULL
and	NULL
retroviral	NULL
tagging	NULL
K	NULL
Blyth	NULL
et	NULL
al	NULL
described	NULL
(	NULL
Vaillant	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1999	NULL
)	NULL
.	NULL

Tumour	NULL
DNA	NULL
was	NULL
screened	NULL
for	NULL
rearrangements	NULL
in	NULL
known	NULL
oncogenes	NULL
using	NULL
DNA	NULL
probes	NULL
as	NULL
follows	NULL
:	NULL
N-Myc	NULL
,	NULL
450	NULL
bp	NULL
PCR	NULL
fragment	NULL
(	NULL
Baxter	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
;	NULL
Pim1	NULL
,	NULL
835	NULL
bp	NULL
PCR	NULL
fragment	NULL
from	NULL
clone	NULL
pPim	NULL
!	NULL

l	NULL
(	NULL
Cupyers	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1984	NULL
)	NULL
;	NULL
Pim2	NULL
,	NULL
2.05	NULL
kb	NULL
cDNA	NULL
fragment	NULL
(	NULL
van	NULL
der	NULL
Lugt	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
;	NULL
Ticl	NULL
,	NULL
1.3	NULL
kb	NULL
PCR	NULL
fragment	NULL
from	NULL
clone	NULL
pMB20	NULL
(	NULL
Breuer	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1989	NULL
)	NULL
;	NULL
Pall	NULL
,	NULL
1.45	NULL
kb	NULL
PCR	NULL
fragment	NULL
from	NULL
clone	NULL
pl1A2	NULL
(	NULL
van	NULL
Lohuizen	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
;	NULL
Bmil	NULL
,	NULL
596	NULL
bp	NULL
PCR	NULL
fragment	NULL
from	NULL
cDNA	NULL
13.1	NULL
(	NULL
van	NULL
Lohuizen	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
;	NULL
Gfil	NULL
,	NULL
1.5	NULL
kb	NULL
Xbal/BamHI	NULL
cDNA	NULL
fragment	NULL
(	NULL
Gilks	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
;	NULL
Dsil	NULL
,	NULL
4	NULL
kb	NULL
BamHI/EcoRI	NULL
fragment	NULL
corresponding	NULL
to	NULL
the	NULL
dsi-SR	NULL
probe	NULL
(	NULL
Vijaya	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
)	NULL
;	NULL
Evi5	NULL
,	NULL
cDNA	NULL
probe	NULL
(	NULL
Liao	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
;	NULL
Ahil	NULL
,	NULL
800	NULL
bp	NULL
Psil/HindIII	NULL
fragment	NULL
from	NULL
clone	NULL
p2-1	NULL
(	NULL
Poiriee	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
)	NULL
;	NULL
RunxI	NULL
,	NULL
158	NULL
bp	NULL
PCR	NULL
fragment	NULL
derived	NULL
from	NULL
the	NULL
exon	NULL
1	NULL
of	NULL
the	NULL
RUNXI1c	NULL
isoform	NULL
(	NULL
Miyoshi	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

c-Myc	NULL
rearrangements	NULL
were	NULL
identified	NULL
using	NULL
a	NULL
human	NULL
c-MYC	NULL
exon	NULL
3	NULL
probe	NULL
,	NULL
(	NULL
Stewart	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
which	NULL
cross	NULL
hybridises	NULL
with	NULL
the	NULL
murine	NULL
c-Myc	NULL
gene	NULL
due	NULL
to	NULL
the	NULL
high	NULL
degree	NULL
of	NULL
homology	NULL
between	NULL
the	NULL
human	NULL
and	NULL
murine	NULL
genes	NULL
.	NULL

Flow	NULL
cytometry	NULL
analysis	NULL
Flow	NULL
cytometry	NULL
analysis	NULL
of	NULL
tumour	NULL
and	NULL
thymic	NULL
tissue	NULL
was	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
Vaillant	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1999	NULL
)	NULL
.	NULL

Acknowledgements	NULL
We	NULL
are	NULL
grateful	NULL
to	NULL
Monica	NULL
Cunningham	NULL
for	NULL
invaluable	NULL
technical	NULL
assistance	NULL
.	NULL

This	NULL
work	NULL
was	NULL
funded	NULL
by	NULL
the	NULL
Cancer	NULL
Research	NULL
Campaign	NULL
and	NULL
the	NULL
Leukaemia	NULL
Research	NULL
Fund	NULL
of	NULL
Great	NULL
Britain	NULL
.	NULL

Donehower	NULL
LA	NULL
,	NULL
Harvey	NULL
M	NULL
,	NULL
Slagle	NULL
BL	NULL
,	NULL
McArthur	NULL
MJ	NULL
,	NULL
Montgomery	NULL
CA	NULL
,	NULL
Butel	NULL
JS	NULL
and	NULL
Bradley	NULL
A	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
.	NULL

Nature	NULL
,	NULL
356	NULL
,	NULL
215-221	NULL
.	NULL

Ducy	NULL
P	NULL
,	NULL
Zhang	NULL
R	NULL
,	NULL
Geoffroy	NULL
V	NULL
,	NULL
Ridall	NULL
AL	NULL
and	NULL
Karsenty	NULL
G.	NULL
(	NULL
1997	NULL
)	NULL
.	NULL

Cell	NULL
,	NULL
89	NULL
,	NULL
747-754	NULL
.	NULL

Gilks	NULL
CB	NULL
,	NULL
Bear	NULL
SE	NULL
,	NULL
Grimes	NULL
HL	NULL
and	NULL
Tsichlis	NULL
PN	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
Biol	NULL
.	NULL

,	NULL
13	NULL
,	NULL
1759-1768	NULL
.	NULL

Girard	NULL
L	NULL
,	NULL
Hanna	NULL
Z	NULL
,	NULL
Beaulieu	NULL
N	NULL
,	NULL
Hoemann	NULL
CD	NULL
,	NULL
Simard	NULL
C	NULL
,	NULL
Kozak	NULL
CA	NULL
and	NULL
Jolicoeur	NULL
P.	NULL
(	NULL
1996	NULL
)	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

,	NULL
10	NULL
,	NULL
1930	NULL
1944	NULL
.	NULL

Harvey	NULL
M	NULL
,	NULL
McArthur	NULL
MJ	NULL
,	NULL
Montgomery	NULL
CA	NULL
,	NULL
Bradley	NULL
A	NULL
and	NULL
Donehower	NULL
LA	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
.	NULL

FASEB	NULL
J.	NULL
,	NULL
7	NULL
,	NULL
938-943	NULL
.	NULL

Kania	NULL
MA	NULL
,	NULL
Bonner	NULL
AS	NULL
,	NULL
Duffy	NULL
JB	NULL
and	NULL
Gergen	NULL
JP	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

,	NULL
4	NULL
,	NULL
1701-1713	NULL
.	NULL

Komori	NULL
T	NULL
,	NULL
Yagi	NULL
H	NULL
,	NULL
Nomura	NULL
S	NULL
,	NULL
Yamaguchi	NULL
A	NULL
,	NULL
Sasaki	NULL
K	NULL
,	NULL
Deguchi	NULL
K	NULL
,	NULL
Shimizu	NULL
Y	NULL
,	NULL
Bronson	NULL
RT	NULL
,	NULL
Gao	NULL
YH	NULL
,	NULL
Inada	NULL
M	NULL
,	NULL
Sato	NULL
M	NULL
,	NULL
Okamoto	NULL
R	NULL
,	NULL
Kitamura	NULL
Y	NULL
,	NULL
Yoshiki	NULL
S	NULL
and	NULL
Kishimoto	NULL
T.	NULL
(	NULL
1997	NULL
)	NULL
.	NULL

Cell	NULL
,	NULL
89	NULL
,	NULL
755-764	NULL
.	NULL

Lazo	NULL
PA	NULL
,	NULL
KleinSanto	NULL
AJP	NULL
and	NULL
Tsichlis	NULL
PN	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
.	NULL

J	NULL
.	NULL

Viro/	NULL
.	NULL

,	NULL
64	NULL
,	NULL
3948-3959	NULL
.	NULL

Leverson	NULL
JD	NULL
,	NULL
Koskinen	NULL
PJ	NULL
,	NULL
Orrico	NULL
FC	NULL
,	NULL
Rainio	NULL
EM	NULL
,	NULL
Jalkanen	NULL
KJ	NULL
,	NULL
Dash	NULL
AB	NULL
,	NULL
Eisenman	NULL
RN	NULL
and	NULL
Ness	NULL
SA	NULL
.	NULL

(	NULL
1998	NULL
)	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
,	NULL
2	NULL
,	NULL
417-425	NULL
.	NULL

Li	NULL
J	NULL
,	NULL
Shen	NULL
H	NULL
,	NULL
Himmel	NULL
KL	NULL
,	NULL
Dupuy	NULL
AJ	NULL
,	NULL
Largaespada	NULL
D	NULL
,	NULL
Nakamura	NULL
T	NULL
,	NULL
Shaughnessy	NULL
JD	NULL
,	NULL
Jenkins	NULL
NA	NULL
and	NULL
Copeland	NULL
NG	NULL
.	NULL

(	NULL
1999	NULL
)	NULL
.	NULL

Nat	NULL
.	NULL

Genet	NULL
.	NULL

,	NULL
23	NULL
,	NULL
348-353	NULL
.	NULL

Liao	NULL
X	NULL
,	NULL
Buchberg	NULL
AM	NULL
,	NULL
Jenkins	NULL
NA	NULL
and	NULL
Copeland	NULL
NG	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
.	NULL

J	NULL
.	NULL

Virol	NULL
.	NULL

,	NULL
69	NULL
,	NULL
7132-7137	NULL
.	NULL

301	NULL
Oncogene	NULL
Runx2	NULL
,	NULL
in	NULL
vivo	NULL
complementation	NULL
and	NULL
retroviral	NULL
tagging	NULL
K	NULL
Blyth	NULL
et	NULL
al	NULL
302	NULL
Lilly	NULL
M	NULL
and	NULL
Kraft	NULL
A	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
57	NULL
,	NULL
5248-5355	NULL
.	NULL

Lilly	NULL
M	NULL
,	NULL
Sandholm	NULL
J	NULL
,	NULL
Cooper	NULL
JJ	NULL
,	NULL
Koskinen	NULL
PJ	NULL
and	NULL
Kraft	NULL
A	NULL
.	NULL

(	NULL
1999	NULL
)	NULL
.	NULL

Oncogene	NULL
,	NULL
18	NULL
,	NULL
4022-4031	NULL
.	NULL

Look	NULL
T.	NULL
(	NULL
1997	NULL
)	NULL
.	NULL

Science	NULL
,	NULL
278	NULL
,	NULL
1059-1064	NULL
.	NULL

Meyers	NULL
S	NULL
,	NULL
Lenny	NULL
N	NULL
,	NULL
Sun	NULL
W	NULL
and	NULL
Hiebert	NULL
SW.	NULL
(	NULL
1996	NULL
)	NULL
.	NULL

Oncogene	NULL
,	NULL
13	NULL
,	NULL
303-312	NULL
.	NULL

Miyoshi	NULL
H	NULL
,	NULL
Ohira	NULL
M	NULL
,	NULL
Shimizu	NULL
K	NULL
,	NULL
Mitani	NULL
K	NULL
,	NULL
Hirai	NULL
H	NULL
,	NULL
Imai	NULL
T	NULL
,	NULL
Yokoyama	NULL
K	NULL
,	NULL
Soeda	NULL
E	NULL
and	NULL
Ohki	NULL
M.	NULL
(	NULL
1995	NULL
)	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

,	NULL
23	NULL
,	NULL
2762-2769	NULL
.	NULL

Mochizuki	NULL
T	NULL
,	NULL
Kitanaka	NULL
C	NULL
,	NULL
Noguchi	NULL
K	NULL
,	NULL
Sugiyama	NULL
A	NULL
,	NULL
Kagaya	NULL
S	NULL
,	NULL
Chi	NULL
S	NULL
,	NULL
Asai	NULL
A	NULL
and	NULL
Kuchino	NULL
Y	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
.	NULL

Oncogene	NULL
,	NULL
15	NULL
,	NULL
1471-1480	NULL
.	NULL

Mochizuki	NULL
T	NULL
,	NULL
Kitanaka	NULL
C	NULL
,	NULL
Noguchi	NULL
K	NULL
,	NULL
Muramatsu	NULL
T	NULL
,	NULL
Asai	NULL
A	NULL
and	NULL
Kuchino	NULL
Y	NULL
.	NULL

(	NULL
1999	NULL
)	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

,	NULL
274	NULL
,	NULL
18659	NULL
18666	NULL
.	NULL

Nesbit	NULL
CE	NULL
,	NULL
Tersak	NULL
JM	NULL
and	NULL
Prochownik	NULL
EV	NULL
.	NULL

(	NULL
1999	NULL
)	NULL
.	NULL

Oncogene	NULL
,	NULL
18	NULL
,	NULL
3004-3016	NULL
.	NULL

North	NULL
T	NULL
,	NULL
Gu	NULL
TL	NULL
,	NULL
Stacy	NULL
T	NULL
,	NULL
Wang	NULL
Q	NULL
,	NULL
Howard	NULL
L	NULL
,	NULL
Binder	NULL
M	NULL
,	NULL
Marin-Padilla	NULL
M	NULL
and	NULL
Speck	NULL
NA	NULL
.	NULL

(	NULL
1999	NULL
)	NULL
.	NULL

Development	NULL
,	NULL
126	NULL
,	NULL
2563-2575	NULL
.	NULL

Ogawa	NULL
E	NULL
,	NULL
Maruyama	NULL
M	NULL
,	NULL
Kagoshima	NULL
H	NULL
,	NULL
Inuzuka	NULL
M	NULL
,	NULL
Lu	NULL
J	NULL
,	NULL
Satake	NULL
M	NULL
,	NULL
Shigesada	NULL
K	NULL
and	NULL
Ito	NULL
Y	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
90	NULL
,	NULL
6859-6863	NULL
.	NULL

Okuda	NULL
T	NULL
,	NULL
van	NULL
Deursen	NULL
J	NULL
,	NULL
Hiebert	NULL
SW	NULL
,	NULL
Grosveld	NULL
G	NULL
and	NULL
Downing	NULL
JR.	NULL
(	NULL
1996	NULL
)	NULL
.	NULL

Cell	NULL
,	NULL
84	NULL
,	NULL
321-330	NULL
.	NULL

Otto	NULL
F	NULL
,	NULL
Thornell	NULL
AP	NULL
,	NULL
Crompton	NULL
T	NULL
,	NULL
Denzel	NULL
A	NULL
,	NULL
Gilmour	NULL
KC	NULL
,	NULL
Rosewell	NULL
IR	NULL
,	NULL
Stamp	NULL
GWH	NULL
,	NULL
Beddington	NULL
RSP	NULL
,	NULL
Mundlos	NULL
S	NULL
,	NULL
Olsen	NULL
BR	NULL
,	NULL
Selby	NULL
PB	NULL
and	NULL
Owen	NULL
MJ	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
.	NULL

Cell	NULL
,	NULL
89	NULL
,	NULL
765-771	NULL
.	NULL

Prendergast	NULL
GC	NULL
.	NULL

(	NULL
1999	NULL
)	NULL
.	NULL

Oncogene	NULL
,	NULL
18	NULL
,	NULL
2967-2987	NULL
.	NULL

Poirier	NULL
Y	NULL
,	NULL
Kozak	NULL
C	NULL
and	NULL
Jolicoeur	NULL
P.	NULL
(	NULL
1988	NULL
)	NULL
.	NULL

J	NULL
.	NULL

Virol	NULL
.	NULL

,	NULL
62	NULL
,	NULL
3985-3992	NULL
.	NULL

Satake	NULL
M	NULL
,	NULL
Nomura	NULL
S	NULL
,	NULL
Yamagachi-Iwai	NULL
Y	NULL
,	NULL
Takahama	NULL
Y	NULL
,	NULL
Hashimoto	NULL
Y	NULL
,	NULL
Niki	NULL
M	NULL
,	NULL
Kitamura	NULL
Y	NULL
and	NULL
Ito	NULL
Y	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
15	NULL
,	NULL
1662-1670	NULL
.	NULL

Oncogene	NULL
Scheijen	NULL
B	NULL
,	NULL
Jonkers	NULL
J	NULL
,	NULL
Acton	NULL
D	NULL
and	NULL
Berns	NULL
A	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
.	NULL

J	NULL
.	NULL

Virol	NULL
.	NULL

,	NULL
71	NULL
,	NULL
9-16	NULL
.	NULL

Schmidt	NULL
T	NULL
,	NULL
Karsunky	NULL
H	NULL
,	NULL
Gau	NULL
E	NULL
,	NULL
Zevnik	NULL
B	NULL
,	NULL
Elsasser	NULL
HP	NULL
and	NULL
Moroy	NULL
T.	NULL
(	NULL
1998	NULL
)	NULL
.	NULL

Oncogene	NULL
,	NULL
17	NULL
,	NULL
2661-2667	NULL
.	NULL

Shirogane	NULL
T	NULL
,	NULL
Fukada	NULL
T	NULL
,	NULL
Muller	NULL
JM	NULL
,	NULL
Shima	NULL
DT	NULL
,	NULL
Hibi	NULL
M	NULL
and	NULL
Hirano	NULL
T.	NULL
(	NULL
1999	NULL
)	NULL
.	NULL

Immunity	NULL
,	NULL
11	NULL
,	NULL
709-719	NULL
.	NULL

Stewart	NULL
MA	NULL
,	NULL
Cameron	NULL
E	NULL
,	NULL
Campbell	NULL
M	NULL
,	NULL
McFarlane	NULL
R	NULL
,	NULL
Toth	NULL
S	NULL
,	NULL
Lang	NULL
K	NULL
,	NULL
Onions	NULL
D	NULL
&	NULL
Neil	NULL
JC	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
.	NULL

Int	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
,	NULL
53	NULL
,	NULL
1023-1030	NULL
.	NULL

Stewart	NULL
MA	NULL
,	NULL
Terry	NULL
A	NULL
,	NULL
O'Hara	NULL
M	NULL
,	NULL
Cameron	NULL
ER	NULL
,	NULL
Onions	NULL
DE	NULL
and	NULL
Neil	NULL
JC	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
.	NULL

J.	NULL
Gen	NULL
Virol	NULL
.	NULL

,	NULL
77	NULL
,	NULL
443-446	NULL
.	NULL

Stewart	NULL
M	NULL
,	NULL
Terry	NULL
A	NULL
,	NULL
O'Hara	NULL
M	NULL
,	NULL
Blyth	NULL
K	NULL
,	NULL
Baxter	NULL
E	NULL
,	NULL
Cameron	NULL
E	NULL
,	NULL
Onions	NULL
D	NULL
and	NULL
Neil	NULL
JC	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
94	NULL
,	NULL
8646-8651	NULL
.	NULL

Vaillant	NULL
F	NULL
,	NULL
Blyth	NULL
K	NULL
,	NULL
Terry	NULL
A	NULL
,	NULL
Bell	NULL
M	NULL
,	NULL
Cameron	NULL
ER	NULL
,	NULL
Neil	NULL
J	NULL
and	NULL
Stewart	NULL
M.	NULL
(	NULL
1999	NULL
)	NULL
.	NULL

Oncogene	NULL
,	NULL
18	NULL
,	NULL
7124-7134.	NULL
van	NULL
der	NULL
Lugt	NULL
NMT	NULL
,	NULL
Domen	NULL
J	NULL
,	NULL
Verhoeven	NULL
E	NULL
,	NULL
Linders	NULL
K	NULL
,	NULL
van	NULL
der	NULL
Gulden	NULL
H	NULL
,	NULL
Allen	NULL
J	NULL
and	NULL
Berns	NULL
A	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
.	NULL

EMBO	NULL
J.	NULL
,	NULL
14	NULL
,	NULL
2536-2544.	NULL
van	NULL
Lohuizen	NULL
M	NULL
,	NULL
Verbeek	NULL
S	NULL
,	NULL
Krimpenfort	NULL
P	NULL
,	NULL
Domen	NULL
J	NULL
,	NULL
Saris	NULL
C	NULL
,	NULL
Radaszkiewicz	NULL
T	NULL
and	NULL
Berns	NULL
A	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
.	NULL

Cell	NULL
,	NULL
56	NULL
,	NULL
673-682.	NULL
van	NULL
Lohuizen	NULL
M	NULL
,	NULL
Verbeek	NULL
S	NULL
,	NULL
Scheijen	NULL
B	NULL
,	NULL
Wientjens	NULL
E	NULL
,	NULL
van	NULL
der	NULL
Gulden	NULL
H	NULL
and	NULL
Berns	NULL
A	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
.	NULL

Cell	NULL
,	NULL
65	NULL
,	NULL
737-752	NULL
.	NULL

Vijaya	NULL
S	NULL
,	NULL
Steffen	NULL
DL	NULL
,	NULL
Kozak	NULL
C	NULL
and	NULL
Robinson	NULL
HL	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
.	NULL

J	NULL
.	NULL

Virol	NULL
.	NULL

,	NULL
61	NULL
,	NULL
1164-1170	NULL
.	NULL

Wang	NULL
Q	NULL
,	NULL
Stacy	NULL
T	NULL
,	NULL
Binder	NULL
M	NULL
,	NULL
Marin-Padilla	NULL
M	NULL
,	NULL
Sharpe	NULL
AH	NULL
and	NULL
Speck	NULL
NA	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
93	NULL
,	NULL
3444-3449	NULL
.	NULL

Zaiman	NULL
AL	NULL
,	NULL
Lewis	NULL
AF	NULL
,	NULL
Crute	NULL
BE	NULL
,	NULL
Speck	NULL
NA	NULL
and	NULL
Lenz	NULL
J	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
.	NULL

J	NULL
.	NULL

Virol	NULL
.	NULL

,	NULL
69	NULL
,	NULL
2898-2906	NULL
.	NULL

